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API   active pharmaceutical ingredient 
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1. INTRODUCTION 
 Nowadays pharmaceutical industry uses many technological operations and the 
number of excipients applied during production is growing. The diversity of the operation 
parameters can influence the quality of the product. With the innovation of production 
protocols, raw materials or waste elimination could be utilized efficiently, the use of toxic 
and/or hazardous reagents and solvents can be avoided in the manufacture and application of 
products. Through the minimization of the number of applied excipients, pharmaceuticals 
would be more “natural”. It is an important aspect for patients to reduce the contamination 
with different chemicals, thereby to decrease the incidence of allergy.   
  
Conventionally used techniques as spray-drying or melt technology can offer 
innovation in the preparation of novel forms. These technologies can be applied in an organic 
solvent free manner, which adapts well to the increasing effort in the industry to introduce 
“green” pharmaceutical practice. Through the optimization of operation parameters, energy, 
production time and costs can be saved. With the reduction of e.g. temperature, the API can 
be protected from decomposition, moreover, the intermedier (microcomposites) or product 
(pastille) can be produced in one single operation step. In the preformulation a DDS can be 
developed using a factorial design, taking special requests (e.g. paediatric preparations) into 
account. 
  
In paediatrics, low amounts of APIs are incorporated in DDSs, so the formulation of 
DDSs plays a key role in the production process. Children are special patients, their 
compliance can be increased by choosing a liked administration route (e.g. per os) instead of 
injections or suppositories. It is known that “value added” preparations are especially 
important in paediatric therapy, which belongs to the category of “unmet medical need”. So 
with the application of conventional technologies as spray-drying (Thi et al., 2012, Aguiar et 
al., 2016, Kaushik et al., 2015) or melt technology (Phaemachud et al., 2010) there is an 
opportunity to develop innovative paediatric preparations (e.g. dose sipping form and 
lozenge) 
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2. AIMS 
The aim of our research work was to apply conventional technologies such as spray-drying and 
melt technologies with new approaches to research and develop innovative PCT containing solid 
DDSs for paediatric administration. The spray-drying process was applied to prepare 
microcomposites for dose sipping form and the melt process was suitable to formulate pastilles 
with “in situ coating” technology as lozenge. For both technologies our research work consisted 
of two parts (i) development of a DDS in preformulation and (ii) incorporation of API in the DDS 
as carrier system. The technologies and investigations are presented in Figure 1. 
 
Fig. 1: Applied technologies and investigations in the research work 
The main aspects of the research work are the following: 
I. to survey the literature background of the preparation of innovative forms used in 
paediatric therapy with conventional methods, spray-drying and melt technology, 
II. to use these technologies innovatively, as organic solvent free methods, for producing 
dosage forms which do not contain any colouring agents or preservatives, 
III. to investigate the excipients used in preformulation studies of carrier systems with 
different screening methods, 
IV. to incorporate a low amount of PCT as model drug in the carriers, thereby designing a 
composition in paediatric therapy, 
V. to suggest a formulation for industrial utilization. 
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3. THEORETICAL BACKGROUND 
3.1. Formulation of innovative products in the pharmaceutical industry 
Conventional pharmaceutical manufacturing is generally accomplished using batch 
processing with laboratory testing conducted on collected samples to evaluate quality. This 
conventional approach has been successful in providing quality pharmaceuticals to the public. 
However, today significant opportunities exist for improving pharmaceutical development, 
manufacturing and quality assurance through innovation in product and process development, 
analysis and control (Web reference 1). Novel trends like nanotechnology or biotechnology are in 
the spotlight of innovation, but the conventionally used technological processes can have new 
approaches, which result in innovative products. Variously applied operations such as spray-
drying or melt technology can be used well for innovative formulation. Using these methods we 
can minimalize the number of excipients and reduce some process steps by being more efficient, 
saving energy and assuring better quality of products, moreover, compositions which satisfy 
specific needs, e.g. paediatric expectations, can be formulated.  
The other aspect of the above-mentioned technologies is the “green” pharmaceutical 
practice, which is a future trend in the pharmaceutical industry. It began in recent years when 
residues of pharmaceuticals were discovered in water, thanks to the development of new 
analytical technologies, which can measure increasingly lower concentrations (Kümmerer et al., 
2007). There have been many suggestions for designing environmentally-benign products and 
processes to address the environmental issues of both products and processes in the research and 
development of new medicines. The basic aspects of green technological techniques are the 
organic solvent reduction, the use of water-based methods in pharmaceutical manufacturing, and 
ongoing programs for reducing emissions, effluents and wastes. Organic solvent reduction can be 
achieved by using amphiphilic materials (e.g. cyclodextrins: Reti-Nagy et al. 2015, Róka et al., 
2015) increasing the water solubility of lipophilic agents or by using novel techniques (e.g. 
microwave processing (Szepes et al., 2005, Szepes et al., 2007)) for the structure modification of 
the API. The above mentioned technologies (spray-drying or melt technology) can be also used 
for the production of “green” pharmaceuticals if the basic aspects of “green” technology (e.g., raw 
materials, solvents, waste management) are complied with.  
So the conventionally applied technologies are suitable to meet new demands and in this 
context to formulate innovative products. In general, these products contain very specific 
carrier(s) because they comply with several criteria (Alpar et al., 2005, Van Arnum et al., 2010). 
The carriers are generally amorphous or semicrystalline polymers which are water-soluble, and by 
using spray-drying the API can be incorporated in them for the purpose of controlled or modified 
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release (Pomázi et al., 2013, Al-Zoubi et al., 2016). Crystalline materials as carriers can be 
processed by melt technologies (Szűts et al., 2011), especially using extrusion (Krause et al., 
2009). 
3.2. Viewpoints of development of paediatrics 
The Paediatric Committee (PDCO) is the European Medicines Agency’s (EMA) scientific 
committee responsible for activities on medicines for children and to support the development of 
such medicines in the European Union by providing scientific expertise and defining paediatric 
needs (Web reference 2). Because of the immature metabolism of children, the most important 
aim in the development of paediatric formulations is the minimization of APIs and auxiliary 
agents (de Zwart et al., 2004). Children are special patients, who have to be convinced to accept 
medication. Their compliance can be largely increased when the taste, colour and smell are in 
harmony in the formulation (Nataha et al., 1999). Instead of artificial sweetening and colouring 
agents and fragrances, natural excipients are preferred to avoid allergic reactions or malformations 
(Farkas et al, 1971). The application of lactose has to be reduced to avoid intolerance (Heyman et 
al, 2006). The classical source of sweetener is sucrose (derived from cane or beet in the form of 
liquid or dry state), dextrose, fructose, glucose, liquid glucose and maltose. The sweetness of 
fructose is perceived rapidly in the mouth as compared to sucrose and dextrose. Fructose is 
sweeter than sorbitol and mannitol and thus used widely as a sweetener. Polyhydric alcohols such 
as sorbitol, mannitol, isomalt and maltitol can be used in combination as they additionally provide 
good mouth-feel and cooling sensation (Mäkinen et al., 2011). Polyhydric alcohols are also less 
carcinogenic and do not have a bitter after taste, which is a vital aspect in formulating oral 
preparations. The sweetness property of most of the polyols is less than half of that of sucrose 
except for xylitol and maltitol, the sweetness of which is similar to that of sucrose (scale of 0.8–
1.0) (Dixit et al., 2009). However, it should be noted that the use of natural sugars in such 
preparations needs to be restricted in people who are on diet or in the case of diabetic patients 
(Mennella et al., 2008, Hutteau et al., 1998). 
3.3. Spray-drying 
Spray-drying is a scalable, well-automatized process, which employs rapid drying from 
solutions, emulsions, suspensions or even melts and foams into dry free-flowing powders (Cal et 
al., 2010). Drying occurs within seconds because of the nozzle atomizes the liquid phase into 
small drops to obtain a maximal surface area in contact with the drying gas. The opportunity of 
varying the operation parameters (inlet temperature, feed rate, aspirator or air flow) during the 
process enables the production of particles with controlled size and morphological aspects. One of 
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the most common applications of spray-drying is in the field of dry powder inhaler production 
(Steckel et al., 2004). The most important requirement of dry powder inhaler formulation is to 
produce monodisperse particles in the size range of 1-10 μm. Spray-drying is an appropriate 
method for this purpose. The conventional process is limited to producing particles with a 
characteristic size below 2 µm mainly because of the atomization technology is based on pressure 
or centrifugal forces, and also due to the limited collection efficiency of the cyclones (Zgoulli et 
al., 1999, Wan et al., 1992, Oneda et al., 2003 Palmieri et al., 1994). The production and 
collection of submicron particles from a solution is only possible with a piezoelectric driven 
vibrating mesh atomizer and a high-efficiency electrostatic dry powder collector. Owing to the 
fast evaporation of the solvent, gentle drying is available, which protects the product from thermic 
decomposition. With the correct selection of the operation parameters, heat sensitive materials can 
be also processed.  By using spray-drying, an amorphous product with good flow properties can 
be produced (Vicente et al., 2013) in one operation step, which can be an intermediate before 
tableting or can provide better water solubility of the active substance. The high quality of the 
spray-dried products is due to the protection of the particles through evaporative cooling during 
the process. It also allows the encapsulation (Tewa-Tagne et al., 2007, Hamishehkar et al., 2010) 
of active agents in a biodegradable polymer or taste masking agent, thus opening a wide spectrum 
of opportunities in the field of particle engineering in pharmaceutical, materials and food science 
(Oliveira et al., 2013). Sterile spray-drying could be also applied for the preparation of stable 
vials, because drying takes place in a closed system and impurities can be avoided.  
Spray-drying is an excellent method for the formulation of DDSs of crystalline carriers. 
Different carriers, e.g. sugar alcohols, are commonly applied for carrier systems (Table 1). 
Particle size reduction can be achieved by the formulation of microcomposites. By setting the 
appropriate operation parameters, micronization and even nanonization can take place in the 
product (Vehring et al., 2008).  
Table 1 Different types of carriers produced with spray-drying 
Carrier API Reference 
PEG 4000 + lactose — Corrigan et al., 2002, Chidavaenzi et al., 2001 
Mannitol — Mönckedieck et al., 2016, Maas et al., 2001,  
Trehalose — 
Ógáin et al., 2011, Islam et al., 2008, Gradon et 
al., 2014, Maurya et al. 2005 
Trehalose + sorbitol — Maurya et al. 2005 
Trehalose + raffinose + HPβCD — Amaro et al., 2015 
Maltodextrin + gum Arabic + 
waxy starch + microcrystalline 
cellulose 
Pomegranate 
juice 
Yousefi et al., 2011 
PEG 6000 + HPMC  Itraconazole Janssens et al., 2008 
PEG 6000 + Soluplus® 
Nifedipine + 
Sulfamethoxazole 
Altamimi et al., 2016 
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PEG 6000 Loperamide Weuts et al., 2005 
Mannitol + Trehalose Meloxicam Pomázi et al., 2011 
PVP Curcumin Paradkar et al., 2004 
PVP + PVAc Diltiazem HCl Al-Zoubi et al., 2016 
PVP + isomalt Celecoxib Ghanavati et al., 2017 
 
3.4. Melt technology 
Melt technology is used increasingly by technological operations in the pharmaceutical 
industry, whereby novel products can be produced efficiently. This green technology involves 
dust-free processes and elastic materials can also be used to produce the final form. There is no 
need for the use of extra organic solvents in the production, therefore there are no residual 
solvents in the product and less environmentally harmful chemical waste is generated in contrast 
with other conventionally used techniques. Melt technology can result in amorphous products, 
which may have higher dissolution rates and bioavailability than those of the corresponding 
crystalline forms (Domian et al., 2002, Broman et al., 2001, Six et al., 2001, Redenti et al., 1996). 
With a fusion method, a solid dispersion of the excipients and active agent can be prepared.  
Melt granulation or thermoplastic granulation is a technique that facilitates the 
agglomeration of powder particles using meltable binders, which melt or soften at relatively low 
temperature (50–90 °C) (Shanmugam et al., 2015). Cooling of the agglomerated powder and the 
consequent solidification of the molten or softened binder complete the granulation process. 
Through a drop-melting method, pastilles can be formed, and pastillation is achieved in one step 
of a conventional melting process.  
Melt extrusion is a process which involves a preliminary stage in which dry powders, drug 
and excipients are mixed by conventional blenders, followed by the addition of a liquid phase and 
further mixing to ensure homogeneous distribution. The wet powder mass is extruded through 
cylindrical dies or perforated screens with circular holes, of typically 0.5–2.0 mm diameter, to 
form cylindrical extrudates, followed by pellet-forming (Breitenbach et al. 2002). 
In situ coating is a novel approach in melt technology developed by Ulrich et al (Wendt et 
al., 2014, Ulrich et al., 2014, Abouzeid et al., 2014), in which the formation of the pastille and its 
coating occur in the same step. Upon using a eutectic mixture of two compounds (e.g. sugars or 
sugar alcohols), phase separation can take place and either of the components may form a coating. 
As phase separation is a thermal process, the recrystallization of the amorphized components can 
be investigated (Patterson et al., 2005, Mah et al., 2015, Löbmann et al., 2013). The drop-melting 
method is a suitable technique for pastille formation, where solidification takes place at the 
surface of the pastilles, corresponding to the recrystallization of the components. Viscosity is a 
critical parameter of this technology: it influences drop size, whereas a relatively high viscosity 
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decreases molecular mobility, thereby hindering the recrystallization process and surface 
solidification (i.e. formation of the “coating” or “shell”). In case of high viscosity, seed crystals or 
ultrasonic agitation can be used to initiate nucleation (Wendt et al. 2014). 
3.5. Dose sipping form 
The dose sipping form is a novel dosage form in paediatric therapy (Tuleu et al., 2005, 
Breitkreutz et al., 2007, Krause et al., 2008). Sipping a single dose of preparation through a 
drinking straw is a novel form of drug administration in paediatric therapy (Walsh et al., 2011). 
Generally granules, pellets, mini tablets, micropellets or microcomposites are filled into a plastic 
drinking straw as drug delivery device (Ziegler et al., 2008) (Fig. 2). The controller located at the 
bottom of the straw acts like a filter. During sipping, the drug containing load will be transported 
to the top of the straw. The cap on the top of the system has two functions, to avoid the 
microbiological contamination of the system and to keep the solid components inside the straw. 
Before use, it has to be removed. The dose sipping form is a flow-through system, which depends 
on the entering liquid. Therefore liquids with low viscosity, e.g. tea, carbonated drinks, water are 
suitable, while viscose liquids like juice with pulp or milk shake can block the system. The 
advantages of the dose sipping form are basically related to patient compliance. Especially 
children often refuse to take tablets or capsules, but drinking a cup of drink through a straw is 
related to natural habit and the bitter taste of drugs can be well tolerated. It can be applied 
discreetly and the dissolved drug can pass in the mouth easily, almost unnoticed. This application 
form is especially suitable for patients who have problems swallowing drug products and 
therefore refuse to take medicine at all (e.g. pediatric or elderly patients). Difficulties with 
administering drugs to children are a widespread problem, which needs improvement with regard 
to off-label use for example (Schirm et al., 2003, Kearns et al., 2003, Standing et al., 2005). The 
first sipping device on the pharmaceutical market was Claroship® (Grünenthal GmbH), which 
contains the macrolide antibiotic clarithromycin in a micropellet form (Yoo 2008). 
 
Fig. 2: Dose sipping form 
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3.6. Lozenges 
Lozenges or pastilles are buccal pharmaceutical preparations containing a drug along with 
flavouring and sweetening agents (Sastry et al., 2000, Bansal et al., 2014). They are mostly 
compressed tablets formulated without a disintegrant and harder than ordinary tablets so that they 
will dissolve slowly in the mouth. Different types of lozenges are hard candy lozenges, soft 
lozenges, chewable lozenges. Lozenges can be used for hospice or chemotherapy patients who 
often experience nausea and in paediatric therapy, e.g. Actiq® the fentanyl citrate containing oral 
transmucosal lozenge (Web reference 3, Sharar et al., 2002). Paediatric patients often show 
improved compliance with lozenges over other types of oral formulations such as tablets or 
capsules (Pundir et al, 2014). Although these lozenges are most often used for a localized effect in 
the mouth (throat lozenges), they can also be used for a systemic effect (Kishorbhai et al., 2014) if 
the drug is well absorbed through the buccal lining or is swallowed. Analgetics and antihistamines 
are commonly utilized in such formulations, which are easy to use in paediatric or geriatric 
therapy and the drug can be kept in contact with the oral cavity for an extended period of time. By 
means of buccal absorption, the disadvantages of peroral administration can be avoided, such as 
the hepatic first-pass metabolism or enzymatic degradation within the gastrointestinal tract, which 
prevent the oral administration of certain classes of drugs, particularly proteins and peptides 
(Sholaei et al., 1998), and additionally a lower amount of drug is needed to achieve the 
therapeutic effect.  In the USA, a buccal pharmaceutical preparation, Meltaways® (Tylenol), 
containing 80 mg of PCT in dextrose carrier, is available as a chewable tablet in paediatric 
therapy. Such solid preparations have the aim of fast release. 
4. MATERIALS AND METHODS 
4.1. Materials 
PCT as model drug was chosen for our experimental work; it was obtained from Sanofi 
Aventis (Frankfurt am Main, Germany) and TRE dihydrate (h-form) from Karl Roth GmbH+Co. 
KG. (Karlsruhe, Germany). This was regarded as 100% crystalline material. Anhydrous TRE (β-
form) was produced by dehydration of TRE dihydrate at 85 °C during 4 h under vacuum (Nagase 
et al., 2002) and checked within 24 h both with DSC and XRPD. XYL, MAN, PEG 2000 and 
PEG 6000 were purchased from Sigma-Aldrich Chemie GmbH (Mannheim, Germany) and SORB 
from Molar Chemicals Ltd. (Halásztelek, Hungary) (Table 2). 
9 
 
Table 2 Materials applied for experimental work 
Material IUPAC name Chemical structure 
 Theoretical 
applications 
Applications in 
our work 
Paracetamol 
(PCT) 
N-(4-
hydroxyphenyl)-
acetamide 
 
analgesic and 
antipyretic agent, a 
selective COX-2 
inhibitor (Hinz et. 
al., 2008) 
Model API in 
microcomposites 
and drop-melted 
pastilles 
Trehalose-
dihydrate 
(TRE 
dehydrate) 
2R,3S,4S,5R,6R)-2-
(Hydroxymethyl)-6-
[(2R,3R,4S,5S,6R)-
3,4, 5-trihydroxy-6-
(hydroxymethyl)oxa
n-2-yl]oxyoxane-
3,4,5-triol dehydrate  
Colour adjuvant; 
flavour enhancer; 
freeze-drying 
agent; humectant; 
stabilizing agent; 
sweetening agent; 
tablet diluent; 
thickening agent 
(Rowe et al., 2009) 
Carrier for PCT 
containing 
microcomposites 
prepared with 
spray-drying 
Anhydrous 
trehalose 
(Anhydrous 
TRE) 
2R,3S,4S,5R,6R)-2-
(Hydroxymethyl)-6-
[(2R,3R,4S,5S,6R)-
3,4, 5-trihydroxy-6-
(hydroxymethyl)oxa
n-2-yl]oxyoxane-
3,4,5-triol anhydrous 
 
Xylitol 
 (XYL) 
(2R,3r,4S)-Pentane-
1,2,3,4,5-pentol 
 
Coating agent; 
diluent; emollient; 
humectant; 
sweetening agent; 
tablet and capsule 
diluent; tablet filler 
(Rowe et al., 2009) 
Component of 
eutectic pastille 
basis 
 
Mannitol 
(MAN) 
(2R,3R,4R,5R)-
Hexane-1,2,3,4,5,6-
hexol 
 
Diluent; 
plasticizer; 
sweetening agent; 
tablet and capsule 
diluent; 
therapeutic agent; 
tonicity agent 
(Rowe et al., 2009) 
Component of 
eutectic pastille 
basis 
Sorbitol 
(SORB) 
(2S,3R,4R,5R)-
Hexane-1,2,3,4,5,6-
hexol 
 
Humectant; 
plasticizer; 
stabilizing agent; 
sweetening agent; 
tablet 
and capsule diluent 
(Rowe et al., 2009) 
Component of 
eutectic pastille 
basis 
Polyethylene 
glycol 2000 
and 6000 
(PEG 2000 
and 6000) 
poly(oxyethylene) 
 
Ointment base; 
plasticizer; solvent; 
suppository base; 
tablet and 
capsule lubricant 
(Rowe et al., 2009) 
Wettability 
enhancer material 
in microcomposites 
and pastilles; 
viscosity enhancer 
in drop-melted 
pastilles 
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4.2. Methods 
4.2.1. Preparation of formulations 
4.2.1.1. Preparation of spray-dried TRE and PCT containing microcomposites 
For the investigation of recrystallization, kinetic TRE dihydrate was spray-dried from 10% 
solutions in water (5.00 g of TRE and 45.0 g of water) using a Büchi 191 Mini Spray Dryer 
(Büchi, Switzerland) (Fig. 3). The aqueous solutions used for the preparation of microcomposites 
contained 7.5% TRE, 1.5% PCT and 1.5% PEGs. The parameters used are given in Table 3 
(Moran et al., 2007). The spray-dried products were stored in a desiccator over cobalt (II) chloride 
contaminated silicon-dioxide (25±2 °C, 32±5% RH) until use. 
 
Fig. 3: Preparation of microcomposites with BÜCHI B-191 spray-dryer 
Table 3 Operation parameters for the preparation of spray-dried TRE 
Operation parameters Settings 
Inlet temperature (°C) 130-140 
Outlet temperature (°C) 75-92 
Nozzle diameter (mm) 0.7 
Feed rate (mL/min) 2 
Pressure (bar) 4.8 
Atomiser flow rate (normoliter/h) 600 
Aspirator (%) 80 
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4.2.1.2. Preparation of PCT containing pastilles with in situ coating technology 
For pastillation, the one-drop pastillation device developed by Kaiser Steel Belt Systems 
GmbH (Krefeld, Germany) was used (Fig. 4A). Physical mixtures of XYL-MAN with PEG as 
carrier additive were prepared and melted in a temperature-controlled double-walled vessel at 110 
°C. A crank shaft moved at constant rate by an engine pressed the mixture in drop form through a 
valve at the bottom of the vessel onto a 25 °C thermostated cooling plate, where it solidified into a 
flat-bottomed pastille (Wendt et al., 2014). 
Eutectic mixtures of XYL-SORB with PEGs as carrier additives were prepared and melted 
in a heated pipette at 110°C. PCT was dispersed in the melted carrier. The melted solid dispersion 
was dropped onto a 25°C thermostated cooling plate, where it solidified to form flat-bottomed 
pastilles (Fig. 4B) (Bülau et al., 1997). Four mixtures were studied, including (1) XYL-SORB 50–
50 wt.% (referred to as XYL-SORB-EUT) without PCT, (2) XYL-SORB with PCT (14.29%) 
(referred to as XYL-SORB-EUT + PCT), (3) XYL–SORB with PCT and PEG 2000 (7.81%) 
(referred to as XYL-SORB + PCT + PEG 2000) and (4) XYL-SORB and PCT with PEG 6000 
(7.81%) (referred to as XYL-SORB + PCT + PEG 6000). 
 
Fig. 4: One-drop pastillation device (1 - temperature controlled plate, 2 - double walled 
vessel, 3 - crank shaft, 4 - engine, 5 - thermostat) (A), heated pipette (B). 
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4.2.2. Instrumental analytical investigations applied for preformulation 
4.2.2.1. X-ray powder diffraction (XRPD)  
XRPD analysis was performed with a Bruker D8 Advance diffractometer (Bruker AXS 
GmbH, Karlsruhe, Germany) with Cu K λI radiation (λ = 1.5406 Å) and a VÅNTEC-1 detector. 
The samples were scanned at 40 kV and 40 mA. The angular range was 3° to 40° 2θ, at a step 
time of 0.1 s and a step size of 0.007° in a quartz holder, at ambient temperature and RH. All 
manipulations, Kα 2-stripping, background removal and smoothing of the area under the peaks of 
diffractograms were performed with DIFFRACTPLUS EVA software. The determination of the 
polymorph forms was based on the Cambridge Crystallographic Data Centre (CCDC ID: 
AI631510) X-ray powder diffractograms.  
4.2.2.2. Differential scanning calorimetry (DSC) 
DSC measurements were carried out with a Mettler-Toledo 821e DSC instrument (Mettler-
Toledo GmbH, Switzerland). Samples were crimped in aluminium pans and were examined at 
different temperature intervals and heating rates under a constant argon flow of 150 mL/min. 
Every measurement was normalized to sample size and was evaluated with STARe Software.  
4.2.2.3. Viscosity measurement 
Rheological measurements were carried out at 110°C using a Physica MCR101 rheometer 
(Anton Paar GmbH, Graz, Austria). A parallel-plate measuring device was used with a diameter 
of 25 mm and 0.20 mm gap height. Shear rate was increased from 0.1 to 100 1/s in a controlled 
rate mode. Shearing time was 300 s. 
4.2.2.4. Contact angle measurement 
The melted compositions were cast on a slide, where they solidified with a flat surface on 
which contact angle measurements were carried out.  The contact angle (θ) was determined by 
means of the sessile drop technique, using an OCA 20 Optical Contact Angle Measuring System 
(Dataphysics, Filderstadt, Germany) and the method of Wu. The liquid mediums used for our 
contact angle measurements included bidistilled water (interfacial tension of polar component (γp) 
= 50.2 mN/m, interfacial tension of disperse component (γd) = 22.6 mN/m) and diidomethane (γp 
= 1.8 mN/m, γd = 49 mN/m). Polarity percentage was calculated from the interfacial tension of 
the polar component (γp) and the surface free energy (γ) values as follows: 
   (1) 
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4.2.3. Dosage form investigations 
4.2.3.1. Determination of flowability parameters 
The parameters of flowability were determined with software-controlled PharmaTest 
PTG-1 powder testing equipment (PharmaTest, Hainburg, Germany). The powder flow was 
controlled by sensors and the time was measured for 100 mL of spray-dried material to flow, the 
angle of repose (α), the volume of the heap and the bulk density of the sample are calculated from 
the mass and height of the formed powder heap. 
4.2.3.2. Particle size distribution (PSD) 
Particle size distributions of the spray-dried powders were determined by laser diffraction 
using Malvern (Malvern Mastersizer Scirocco 2000; Malvern Instruments Ltd., Worcestershire, 
UK). Air was used as the dispersion medium for the microcomposites from the entrance to the 
sample cell. Approximately 500 mg of product was loaded into the feeder tray. The particle size 
distribution was characterized by the d(0.5), D[3,2] and D[4,3] value. 
4.2.3.3. Scanning electron microscopy (SEM)  
The morphology of the particles was examined by SEM (Hitachi S4700, Hitachi Scientific 
Ltd., Tokyo, Japan). A sputter coating apparatus (Bio-Rad SC 502, VG Microtech, Uckfield, UK) 
was applied to induce electric conductivity on the surface of the samples. The air pressure was 
1.3–13.0 MPa. Briefly, the samples were sputter-coated with gold–palladium under an argon 
atmosphere, using a gold sputter module in a high-vacuum evaporator and the samples were 
examined at 10 kV and 10 A. The shape of PCT containing microcomposites was examined by 
analysing several SEM images with the ImageJ software environment. 
4.2.2.4. Raman spectroscopy (Raman) 
The uniformity of PCT content in the pastilles was investigated with Cobalt TRS 100 
instrument (Cobalt Light Systems Ltd., Abingdon, UK) over the wavenumber range 1700-200 
1/cm. Each reported spectrum is the average of at least 3 scans with an exposure time of 1 s, a 
laser power of 0.4 W and a laser spot size of 8 mm. 
For the determination of different PCT polymorphs, a Thermo Fisher DXR Dispersive 
Raman instrument (Thermo Fisher Scientific. Inc., Waltham, MA, USA) equipped with a CCD 
camera and a diode laser operating at a wavelength of 780 nm was used. Raman measurements 
were carried out with a laser power of 12 mW at a slit aperture size of 25 µm on a spot size of 2 
µm, with an exposure time of 6 s, for a total of 48 scans in the spectral range 1700-200 1/cm with 
cosmic ray and fluorescence corrections. 
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The PCT-containing pastilles were investigated by Raman chemical mapping to localize 
the different forms of PCT in the composition. A 2775 μm * 60 μm size surface were analysed 
with step size of 10 μm with an acquisition time of 3 sec per spectrum. The mapping was carried 
out with a laser power of 12 mW at 25 µm slit aperture size. The chemometric processing of 
vibrational chemical images was studied by multivariate curve resolution alternating least squares 
(MCR-ALS) chemometric method. The Raman spectra were normalized in order to eliminate the 
intensity deviation between the measured areas. 
4.2.2.5. Geometrical parameters and hardness 
The diameter and the height of 20 pastilles were measured with a screw micrometer 
(Starrett Co., Athol, MA, USA) and their masses were measured using an analytical scale (Mettler 
Toledo AX205 Delta Range analytical scale, Mettler Toledo GmbH, Greifensee, Switzerland).    
 The hardness of the pastilles was analysed by a Heberlein hardness tester (Heberlein & 
Co. AG, Switzerland). Five randomly selected pastilles were investigated to calculate the average 
and the standard deviation. 
4.2.2.6. Drug content determination 
100 mg of microcomposites and a powdered pastille plus 15 mL of methanol was shaken 
in a 100 mL volumetric flask until the powder got dissolved. Then 85 mL of water was added to 
adjust the volume to 100 mL. Next, a 1 mL aliquot was transferred to a 100 mL volumetric flask 
and was mixed with methanol/water 15:85 to 100 mL. The dissolved amount of PCT was 
analysed spectrophotometrically at 244 nm (PerkinElmer, Lambda 20 spectrophotometer, 
Dreieich, Germany) (Behera et al., 2012). 
4.2.4.5. In vitro dissolution studies 
The dissolution profile of PCT from microcomposites and pastilles of different 
compositions was determined according to the USP-2 paddle method (Pharmatest, Heinburg, 
Germany). The rotating velocity of the paddle within the dissolution vessel was 75 rpm. The 
dissolution studies were carried out in 100.0 mL of phosphate buffer solution at pH 6.8 ± 0.1 
characteristic of the oral cavity and at normal body temperature of 37 ± 0.5°C, as well as in 900.0 
mL of 0.1 N HCl at a gastric pH of 1.2 ± 0.1 at 37 ± 0.5°C (Mashru et al., 2005, Gahel et al., 
2009). At predetermined time intervals, 5 mL samples were taken and filtered immediately (using 
a Minisart SRP 25, Sartorius, Göttingen, Germany; pore size: 0.2 μm,), and the amount of 
dissolved drug was determined spectrophotometrically at 244 nm (PerkinElmer, Lambda 20 
spectrophotometer, Dreieich, Germany). 
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5. RESULTS AND DISCUSSION 
5.1. Preformulation studies of TRE based microcomposites  
In the preformulation we investigated and quantified the physical changes of the spray-
dried amorphous TRE through the use of various analytical techniques. The recrystallization 
kinetics can be followed, which is important because of the appearance of polymorphic forms. 
TRE was chosen for carrier because it is often used as a sweetening or taste masking agent 
formulated with spray-drying (Ógáin et al., 2011, Islam et al., 2008, Pomázi et al., 2011, Maurya 
et al., 2005, Maurya et al., 2005, Moran et al., 2007, Amaro et al., 2015) in pharmaceutical 
technology.  
5.1.1. Determination of calibration curves with XRPD 
Physical mixtures of spray-dried (amorphous) and the two different crystalline forms of 
TRE were prepared to achieve 0, 5, 10, 30, 50, 70, 90, 95 and 100% crystalline content by mass. 
The components were weighed to a total amount of 0.50 g and were mixed until homogeneous in 
a trituration mortar. The peak intensities of the individual components are proportional to the 
quantities of components in the mixture. Three characteristic peaks from each were selected from 
the diffractograms of TRE dihydrate (at 8.531°, 12.552° and 14.224° 2θ) and anhydrous TRE (at 
6.572°, 20.351° and 24.792° 2θ). Multiple linear regression (MLR) was used to determine the 
calibration curve. The dependent variable was the crystallinity and the independent variables were 
the relative intensity values at chosen 2θ values. After the determination of the degree of 
crystallinity from the w/w ratio of the physical mixtures, a calibration curve was fitted. The linear 
regression of the data produced an r2 = 0.995 and a slope of 0.990 for TRE dihydrate (Fig. 5A.). 
For anhydrous TRE, r2 = 0.997 and the slope was 0.997 (Fig. 5B.). 
 
Fig. 5: Relation between predicted and actual crystallinity of physical mixtures of crystalline TRE 
dihydrate - amorphous form (A), anhydrous TRE - amorphous form (B) determined by 
conventional XRPD 
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Because of the well-correlating r2 values, the degree of crystallinity can be quantified. 
5.1.2. Calculation of recrystallization kinetics 
The recrystallization kinetics was modelled by using the Avrami equation (Eq. 2): 
)exp(1 nKt  (2) 
where α is the fraction of recrystallized TRE at time t, K is the rate constant and n is the Avrami 
index, a parameter characteristic of the nucleation and growth mechanism of crystals.  
The fraction of recrystallized TRE (α) was calculated from the area under the 
characteristic peaks using the following equation (Eq. 3):  
 (3) 
where α is the crystalline fraction, A is the area of characteristic crystalline peaks and amorphous 
sign. The XRPD instrument was calibrated every day with corundum during the 28-day 
measurement to minimalize the day to day intensity changes in XRPD emission.  
The Avrami parameters were obtained from the experimental data by using the double 
logarithmic form of Eq. (4):  
tnK lnln)]1ln(ln[    (4) 
The activation energy of the recrystallization was calculated by using the Arrhenius 
equation (Eq. 5): 







RT
E
kk aexp0  (5) 
In the model, k is the rate constant at temperature T, k0 is the frequency factor, R is the gas 
constant and Ea is the activation energy. The logarithmic form of Eq. (5) allows the determination 
of the activation energy (Eq. 6) (Mazzobre et al., 2001). 
RT
E
kk a 0lnln  (6) 
5.1.3. Hot-humidity stage XRPD analysis (HH-XRPD) 
For the development and qualification of solid compositions, it is important to investigate 
and determine changes of the crystalline phases or the effect of crystallization inhibitor when 
materials are exposed to changing humidity and temperature. By increasing the RH in small 
intervals (10%) at the exact temperature, good estimation could be gained in a few hours at the 
exact temperature about the behaviour of the samples, which could be reflected in the results of 
the conventional stability test. There is no need for additional hygrostats and extra samples, the 
measurement takes place directly in the chamber connected to the instrument. The RH was set at 
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10, 20, 30, 40, 45, 50, 60 and 70% at 40 °C, 60 °C and 70 °C controlled temperatures, and the 
samples were kept in each condition for 1 h before measurement. These investigations are not 
only important to establish procedures for storage, production and shipment, but also emulate the 
digestion of the respective drug and its first interactions with the patient. In this context HH-
XRPD was used to predict the tendency to recrystallization, which is presented in Table 4. 
Table 4 The degree of crystallinity calculated from the HH-XRPD data (A: amorphous, h-
form: dihydrate, β-form: anhydrous)  
Time; RH 
(min; %) 
Form of TRE Degree of crystallinity (%) 
40 °C 60 °C 70 °C 40 °C 60 °C 70 °C 
0; 0 A A A 0 0 0 
60; 10 A A A 0 0 0 
120; 20 A A A 0 0 0 
180; 30 A A h-form 0 0 11.7 
240; 40 A A h-form 0 0 31.1 
300; 45 h-form h-form h-form 14.8 27.2 65.2 
360; 50 h-form h-form h-form 35.8 62.4 100 
420; 60 h-form h-form β/h-form 70.2 78.8 100 
480; 70 h-form h-form β/h-form 100 100 100 
The samples measured at 40 and 60 °C were amorphous up to 45% RH, when recrystallization 
began in the TRE dihydrate polymorph. The samples measured at 70 °C were amorphous up to 
30% RH, than they recrystallized to dihydrate form and up to 60% RH the anhydrous form 
appeared, too. The determination of the polymorph forms was based on the Cambridge 
Crystallographic Data Centre (CCDC ID: AI631510) X-ray powder diffractograms (Fig. 6). 
18 
 
 
Fig. 6: The recrystallized TRE polymorphs at 40, 60 and 70 °C controlled temperatures 
The diffractograms measured at 40, 60 and 70 °C showed an increasing tendency to 
recrystallization. The relative intensities and integrals of the peaks increased with the temperature, 
therefore the temperature influences the tendency of TRE to recrystallize. 
To investigate the temperature dependence of recrystallization, the recrystallized fractions 
were plotted against time for each temperature. As the calibration showed, before XRPD the 
method could be used for quantitative measurements. The curves obtained by fitting the Avrami 
Eq. (2) were in good agreement (r2 > 0.992) with the experimental points (Fig. 7). 
 
Fig. 7: Crystallization kinetics by fitting the Avrami equation to the HH-XRPD data 
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The sigmoidal curves showed that increased temperature accelerates the recrystallization and 
reduces the crystallization half-time. To acquire information about the velocity of the process and 
the dimensions of crystal growth, the parameters K and n were determined by using the linearized 
Avrami equation (Eq. 4) (Fig. 8) and the activation energy was calculated via the logarithmic 
form of the Arrhenius model (Eq. 6) (Table 8).  
 
Fig. 8: Determination of the Avrami parameters n and K from HH-XRPD data 
5.1.4. Analysis of samples stored in hygrostats (XRPD) 
Spray-dried products were stored for 28 days at 40 °C and 60 °C, in 3-3 hygrostats, where 
the RH was set to 30%, 40% and 50% RH. In each desiccator and hygrostat, there was a digital 
humidity meter during the storage for controlling the relative humidity (Table 5). With this 
investigation we can get information about suitable storage conditions of spray-dried products. 
Table 5 Different storage conditions of amorphous samples 
Temperature (°C) RH (%) Storage time (day) 
40±2 
30±5 28 
40±5 28 
50±5 28 
60±2 
30±5 28 
40±5 28 
50±5 28 
The fractions of recrystallized TRE were measured at different times during the 28 days of 
storage. The conventional XRPD analysis showed that the samples stored at 40 °C, 30% and 40% 
RH, and at 60 °C, 30% RH remained amorphous. The samples stored at 40 °C, 50% RH 
recrystallized in the dihydrate form. The storage conditions at 60 °C, 40% RH resulted in the 
recrystallization of the anhydrous form, and in the sample stored at 60 °C, 50% RH, both 
polymorphs appeared, the h-form (dihydrate) and the β-form (anhydrous) (Fig. 9). 
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Fig. 9: Top-view pictures of XRPD investigations of samples stored for 28 days at 40 °C, 
50% RH (A), 60 °C, 40% RH (B) and 60 °C, 50% RH (C) 
Figure 9B shows that the stripe at 8.531° 2θ disappears after storage for 14 days, and there is a 
polymorph conversion of TRE dihydrate into the anhydrous form, confirmed by the characteristic 
thick stripe at 6.572° 2θ. Figures 9A and C do not indicate any polymorph conversion. The 
diffractograms measured after 28 days of storage are shown in Fig. 10. 
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Fig. 10: Diffractograms of samples stored for 28 days under different conditions, compared 
with TRE forms in CCDC  
The degree of crystallinity of the recrystallized polymorphs was calculated by evaluating the 
diffractograms in Fig. 10 according to the MLR model. The results showed that amorphous 
fractions remained in the samples, but decreased at higher temperature and RH (Table 6) in 
comparison with diffractograms of TRE in CCDC. 
Table 6 The degree of crystallinity calculated from the XRPD data after 28 days 
Condition 
t; RH 
(°C; %) 
Form of TRE Quantity (%) 
amorphous dihydrate 
(h-form) 
anhydrous 
(β-form) 
amorphous dihydrate 
(h-form) 
anhydrous 
(β-form) 
40; 30 + - - 100 0 0 
40; 40 + - - 100 0 0 
40; 50 + + - 63.1 36. 9 0 
60; 30 + - - 100 0 0 
60; 40 + - + 25.5 0 74.5 
60; 50 + + + 0.4 58.2 41.5 
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By means of the 28-day stability tests, the different recrystallized polymorph forms can be 
detected and quantified. The results showed that at 40 °C and 50% RH the dihydrate was detected, 
but the bulk of the investigated sample remained amorphous. Storage at 60 °C and 40% RH 
resulted in the appearance of the anhydrous form and only a minor proportion of the sample 
remained amorphous. At 60 °C and 50% RH, both polymorphic forms were detected and almost 
the whole sample recrystallized. This conventional method is often used as a long-term stability 
test in the development of a drug delivery system. 
5.1.5. DSC investigation 
Samples loaded at different RH (10, 20, 30, 40, 45, 50 and 70%) in the XRPD humidity 
chamber for 1 h were crimped in aluminium pans and were examined in the temperature interval 
25-250 °C at a heating rate of 10 °C/min. The amount of recrystallized TRE dihydrate was 
calculated from the integral of the endothermic peaks at 108 °C, which is the melting point of 
TRE dehydrate β-form. Table 7 shows the enthalpy changes of melting and the calculated 
crystalline fraction at different temperatures with increasing the RH. 
Table 7 Enthalpy changes (ΔH) of melting and the crystalline fraction (α) at different 
temperatures with increasing the RH 
RH (%) 
ΔH (J/g) α (%) 
40 °C 60 °C 70 °C 40 °C 60 °C 70 °C 
30 - - 17.1 0 0 11 
40 - - 27.3 0 0 17.6 
45 44.5 33.0 128.1 28.7 21.3 82.7 
50 63.8 66.0 137.6 41.2 42.6 88.8 
60 130.4 123.5 141.4 84.2 79.7 91.3 
70 153.5 153.0 153.8 99.1 98.8 99.3 
 
The amount of crystalline fractions showed that the recrystallization of the amorphous sample is 
more significant with increasing RH and at 70% RH total recrystallization of the samples occurred 
at all 3 temperatures. The comparison of these results with those in Table 4 shows that DSC and 
HH-XRPD measurements correlate well. With this method, only the fraction of recrystallized 
TRE dihydrate can be determined. Since the anhydrous form has high melting point, the dihydrate 
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form is conversed into the anhydrous form resulting in false measurement data. However, the 
method can be used for fast stability testing during the preformulation.    
The crystalline fractions calculated from the DSC data (Table 7) were plotted against time 
for each temperature with r2 > 0.983 (Fig. 11). 
 
Fig. 11: Crystallization kinetics by fitting the Avrami equation to the DSC data 
The sigmoidal curves showed that increased temperature accelerates the recrystallization and 
reduces the crystallization half-time. To acquire information about the velocity of the process and 
the dimensions of crystal growth, the Avrami parameters should be determined. The parameters K 
and n were determined by using the linearized Avrami equation (Eq. 4). A plot of ln [-ln (1-α)] 
against ln (t) yields a straight line with slope n and intercept ln K (Fig. 12). The activation energy 
was calculated via the logarithmic form of the Arrhenius model (Eq. 6). Table 8 shows the 
parameters of the recrystallization process. 
 
Fig. 12: Determination of Avrami parameters n and K from DSC data 
24 
 
Table 8 Avrami parameters and activation energy of recrystallization investigated with HH-
XRPD and DSC 
Method t (°C) n K Ea (kJ mol-1) 
HH-XRPD 
40 3.373 5.79E-04  
47.215 
 
60 3.566 1.70E-03 
70 3.934 2.84E-03 
DSC 
40 3.378 1.69E-03 
41.645 60 2.989 5.98E-03 
70 3.156 6.29E-03 
The values of rate constant K show that increasing temperature accelerates the recrystallization 
process. There are differences between the measurement results of the two methods, but the results 
correlate well. The comparison of the HH-XRPD data with the DSC measurements demonstrates that 
increasing temperature accelerates the recrystallization and reduces the crystallization half-time. The 
parameters K and n were determined by using the linearized Avrami equation (Eq. 3) (Fig. 12).  
5.2. Incorporation of PCT in the microcomposites 
After the preformulation studies of TRE containing carrier systems PCT was incorporated 
with the aim to produce microcomposites for preparation of dose sipping form. Because spray-drying 
results in amorphization in TRE, the dissolution time is fast enough for the liberation of the API to 
occur in the liquid media during application.  By assuring low RH during the storage of the 
preparation, the amorphous form can be preserved. To reduce the adhesion of microparticles due to the 
electrostatic charge, PEGs were added to the formulation. After spray-drying the PCT-containing 
microcomposites, dosage form investigations were carried out. First, we studied the moisture content, 
flowability of the products, then the structure of microcomposites was checked before and after 
storage, finally the drug amount and the dissolution extent were measured. 
5.2.1. Moisture content determination and flowability study 
Analysing the moisture content of microcomposites is important because of the 
microbiological stability, as TRE is a good soil of microorganisms and to avoid recrystallization. That 
is why we tried to minimalize it in the samples. Moisture content determination was carried out with 
thermogravimetric analysis (Mettler-Toledo TG/DSC1) in the temperature interval 25-300 °C, at a 
heating rate of 10 °C/min under constant argon (150 mL/min) and nitrogen (60mL/min) flow. Another 
important parameter is flowability because of the filling of microcomposites in the straw. The 
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flowability parameters and moisture content of spray-dried PCT containing samples were determined 
(Table 9).  
Table 9 Moisture content and flowability parameters of spray-dried samples 
Sample 
Flow 
time 
(s) 
Angle of 
repose 
(°) 
Volume 
 
(mL) 
Mass 
 
(g/100 mL) 
Bulk 
density 
(g/mL) 
Moisture 
content 
(%) 
TRE-PCT 16.5 19.6 46.6 16.65 0.167 6.24 
TRE-PCT- PEG 2000 12.6 8.8 27.5 14.31 0.143 4.05 
TRE-PCT- PEG 6000 9.6 6.3 20.2 12.81 0.128 2.79 
It can be concluded that the PEG containing samples have shorter flow time because of the low 
electrostatic charge. PEG containing samples also have lower moisture content, which can predict 
a better microbiological stability. 
5.2.2. DSC investigation of spray-dried samples 
 The thermal behaviour of the fresh spray-dried samples and different compositions after 3 
months of storage in a desiccator (25±2 °C, 32±5% RH) was investigated with DSC (Fig. 13). 
 
Fig. 13: DSC curves of the different compositions 
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When comparing the DSC curves of spray-dried samples to physical mixtures it can be 
concluded that spray-drying resulted in amorphization in the TRE-PCT-PEG samples, the glass 
transition temperatures (Tg) can be detected. PEGs preserved their semicrystalline form, TRE and 
PCT have no influence on their structures and the melting points can be detected. Each of the 
three compositions was stable up to 160 °C, over it the recrystallization of TRE anhydrous form 
took place, which confirms its melting point at 208 °C. The samples stored for 3 months remained 
amorphous and stable up to 160 °C. 
5.2.3. XRPD investigation 
The structure of the spray-dried and the stored samples was also investigated with XRPD 
and compared to that of the physical mixtures (Fig. 14). 
 
Fig. 14: XRPD diffractograms of spray-dried samples and physical mixtures 
The XRPD diffractograms show spray-drying resulted in amorphization, the characteristic 
peaks of crystalline agents could not be observed, the samples remained amorphous after 3 
months of storage.  
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5.2.4. PSD and SEM images 
As moisture content determination and flowability studies showed that PEG containing 
samples have better properties, the further investigations were carried out only with these 
samples. The particle size (Fig. 15) and the PSD (Table 10) of spray-dried PEG containing 
samples were determined with laser diffraction analysis.  
 
Fig. 15: PSD of TRE-PCT-PEG containing samples 
Table 10 Influence of different PEGs on PSD of microcomposites 
Samples d(0.5) [μm] D[3,2] [μm] D[4,3] [μm] 
TRE-PCT-PEG 2000  10.711 8.893 13.685 
TRE-PCT-PEG 6000  6.897 5.667 7.938 
Laser diffraction analysis shows the average particle size of PEG 6000 containing 
microcomposites is smaller than that of PEG 2000 containing ones. Spray-drying resulted in 
monodisperse distribution in both PEG containing compositions. Their morphology was 
investigated with SEM (Fig. 16). 
TRE-PCT-PEG 2000 TRE-PCT-PEG 6000
 
Fig. 16: SEM images of PEG containing samples 
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The SEM images reveal that in both cases spherical microcomposites were produced, their surface 
was uniform, no fracturing could be observed on it.  
5.2.5. Drug content determination 
Before the in vitro dissolution studies, the drug content of the microcomposites was 
determined. 100 mg from each composition (TRE-PCT, TRE-PCT- PEG 2000 and 
TRE-PCT-PEG 6000) was investigated. The calculated and measured PCT contents were 14.29 
mg, spectrophotometrically 14.24 ± 0.71 mg, respectively. 
5.2.6. In vitro dissolution 
According to the drug content determination, 280.89 mg of microcomposites contains the 
required dose of PCT (40.0 mg). In the in vitro dissolution studies three parallel measurements 
were carried out, in which the PCT dissolutions of different PEG containing microcomposites 
were compared at the oral cavity pH (pH 6.8±0.1) and in the gastric juice (pH 1.2±0.1) (Figs 17 
and 18). 
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Fig. 17: Dissolution extents of microcomposites at the oral cavity pH of 6.8±0.1 and 37±0.5 
°C (average value±SD, n=3) 
In both cases, the PCT was practically fully dissolved from the microcomposites in the 
medium of the oral cavity (pH 6.8±0.1) within 2 min. The fast dissolution kinetics can be 
explained with the high specific surface. 
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Fig. 18: Dissolution extents of microcomposites at the gastric pH of 1.2±0.1 and 37±0.5 °C 
(average value±S.D., n=3) 
In the acidic medium (pH 1.2±0.1), the PCT also practically fully dissolved from the 
microcomposites within 2 min. A burst effect can be observed on the curve of the PEG 2000 
containing product, which can be explained with the amorphization of the sample. 
Summary 
In the preformulation study of spray-dried microcomposites, the three analytical methods 
(HH-XRPD, XRPD, DSC) were compared to investigate the recrystallization of amorphous TRE. 
In this light, the suitable choice of the storage conditions can protect the amorphous TRE samples 
from crystallization. In view of these results, TRE is applicable for formulating API containing 
microcomposites with spray-drying. 
After the incorporation of PCT in microcomposites it was revealed that the use of PEGs in 
the formulation decreased the electrostatic charge of the particles and produced good flow 
properties. Spray-drying resulted in amorphization in the samples (TRE, PCT), Tg could be 
determined, PEGs remained semicrystalline in the formulations. The amorphous compositions are 
stable under 160 °C, at higher temperature the recrystallization of amorphous TRE begins. After 3 
months the samples remain amorphous at ambient temperature and RH. Dissolution studies 
showed PCT was fully dissolved in the medium after 2 min. According to these results, the two 
PEG containing compositions can be utilized for the formulation of dose sipping form and 
paediatric application. 
30 
 
5.3. Preformulation of PCT containing pastilles produced with melt technology 
5.3.1. Phase diagrams of sugar alcohols 
In the development of a carrier system (DDS) for melt technology, the physico-chemical 
interactions of the components should be examined in order to determine the optimum 
composition for pastille-forming method.  
Determination of the phase diagram of XYL–MAN and XYL–SORB physical mixtures is 
necessary to find the eutectic melting temperature and to understand the mechanism of 
crystallization of the pastille. 100 mg of solid XYL–MAN and XYL–SORB dispersions of 
different ratios were prepared and the melting temperatures for the phase diagram were collected 
with DSC (Fig. 19).  
 
 
Fig. 19: Phase diagrams of the XYL–MAN (A) and XYL–SORB (B) systems by plotting the 
melting points of the compositions versus their different mass ratios 
  
The point of interception of the curves on the binary phase diagrams indicated the eutectic 
concentration at 90 wt.% XYL–10 wt.% MAN and 50 wt.% XYL–50 wt.% SORB. The melting 
temperature of pure XYL was detected at 97.6°C. The melting temperature of the XYL–MAN 
eutectic composition dropped to 95.5 °C, of XYL-SORB eutectic composition proved to be 76.9 
°C. The phase diagrams suggest that phase separation between XYL–MAN and XYL-SORB is 
theoretically possible. The melting temperature of pure MAN (169.5 °C) can be decreased by 
more than 70 °C in the eutectic mixture. 
Eutectic melting enthalpy ΔH (J/g) values for the different XYL–MAN and XYL–SORB 
dispersions, as determined by the integration of the eutectic peak area, were plotted versus the 
mass ratio of xylitol in order to construct the Tamman’s triangle showing the eutectic ratio of 
sugar alcohols at the maximal melting enthalpy value (Fig. 20) (Rycerz et al., 2013). 
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Fig. 20: Construction of the Tamman’s triangles of XYL–MAN (A) and XYL–SORB (B) by 
plotting the eutectic melting enthalpies ΔH versus their different mass ratios 
The enthalpy of the eutectic compositions is maximal (ΔHXYL–MAN =191.2 J/g; ΔHXYL–
SORB=101.1 J/g) and converges to zero for compositions corresponding to the pure components. 
These data confirm that XYL–MAN form a eutectic mixture in a 90–10 wt.% and XYL–SORB in 
50–50 wt.% ratio. Because the eutectic mixture of XYL and MAN results in rapid solidification, it 
is necessary to apply PEG as softener material. According to the literature data, it has no influence 
on the recrystallization of the components (XYL, MAN and PCT) but promotes the formation of 
pastille dosage form (Bashiri-Shahroodi, 2007). The ternary phase diagram of xylitol, mannitol 
and PEG 6000 was also investigated in certain cases. 100 mg solid XYL–MAN samples in 
different ratios were prepared with a constant amount of PEG 6000 (7.81 %) to determine the 
ternary phase diagram. The melting temperatures were analysed by DSC at a heating rate of 
2 °C min-1. Parabolic curve fitting was applied to investigate the effect of the polymer on the 
eutectic concentration (Fig. 21). It turned out that, in the presence of this quantity of PEG 6000, 
the eutectic concentration of xylitol and mannitol was at 80 wt.%  xylitol and 20 wt.% mannitol.  
 
Fig. 21: The XYL–MAN phase diagram in the presence of a fixed amount of PEG (7.81 mg 
per 100 mg) 
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After identifying the eutectic composition of XYL–MAN in the presence of PEG 6000, 
we investigated the influence of PEG in the XYL–SORB composition, too. PEG 2000 (7.81%) 
and 6000 (7.81%) were added to the eutectic dispersions. The melting point (Tm) of the samples 
was examined in the temperature interval of 25-170 °C at a heating rate of 2°C/min under a 
constant argon flow of 150 mL/min (Fig. 22). Next, the samples were cooled to –40°C and then 
reheated to 110°C at a heating rate of 2°C min-1 under a constant argon flow of 150 mL/min and 
a nitrogen flow of 50 mL/min to study glass transition (Tg) (Table 11).  
 
Fig. 22: DSC curves of the components, A: MAN, B: XYL, C: SORB, D: PEG 2000, E: PEG 
6000, F: eutectic mixture of XYL-MAN with PEG 6000, G: eutectic mixture of XYL-SORB 
with PEG 2000, H: eutectic mixture of XYL-SORB with PEG 6000 
 
It was found that during heating both PEGs melt separately from the compositions and 
have no influence on the eutectic composition of XYL–SORB. We suppose that the lower Tm and 
Tg values of the XYL–SORB–EUT+PEG 6000 mixture result from the interaction of PEG 6000 
with one of the eutectic components (Table 11). 
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Table 11 Melting points (Tm) and glass transitions (Tg) of the XYL–SORB–PEG 
compositions and the pure components studied 
Composition 
First heating Cooling Second heating 
Tm (°C) TmPEG (°C)  Tg (°C) Tcryst (°C) Tm (°C) Tg (°C) 
XYL 97.6 – – – – –19.5 
MAN 166.1 – – 114.1 166.1 – 
SORB 98.2 – – – – –1.6 
XYL–MAN–EUT 95.5 – – – – –16.9 
XYL–MAN–EUT 
+ PEG 6000 
97.6 60.5 – – 60.3 –16.2 
XYL–SORB–EUT 76.9 – – – – –10.9 
XYL–SORB–EUT 
+ PEG 2000 
77.6 51.8 – – 51.8 –11.0 
XYL–SORB–EUT 
+ PEG 6000 
72.4 60.0 – – 60.1 –14.3 
5.3.2. Optimization of eutectic formula 
 Our target was to develop a pastille containing 40 mg PCT. Since PEG 6000 was found to 
influence the eutectic concentration of XYL–MAN, a Box-Behnken experimental design was 
carried out to optimize the formulation as concerns the carrier. Three experimental factors (XYL, 
MAN and PEG 6000) were varied in the design, at 3 levels in 15 runs so as to construct the 
surface plot for the optimization process (Table 12) according to the recrystallization time.  
Table 12 Variables and their levels in the Box-Behnken design 
  Levels  
 -1 0 1 
Independent variables 
(factors) 
Contents of components (wt.%) 
XYL  48.13  61.25  75.94  
MAN  6.88  15.31  12.31 
PEG 6000 0 7.81  15.63  
Recrystallization begins on the shell of the pastille and tends inwards to the core. If this process 
takes place too quickly, the dissolved melt components with higher melting temperatures (PCT 
and MAN) recrystallize first and their crystals sink to the bottom of the pastille, resulting in an 
inhomogeneous distribution. A composition was first sought in which recrystallization was slow 
enough to preserve the homogeneous distribution of the components. The experimental results 
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showed that each of the three components exerted a significant effect on the recrystallization. At a 
95% confidence level, the coefficients differed from zero and the P-values were <0.05, the time of 
recrystallization depending significantly on the fractions of the components. The surface plot 
illustrates the recrystallization times of the different component ratios (Fig. 23). 
 
Fig. 23: Surface plot illustrating optimization of the XYL–MAN–PEG 6000 containing 
carrier 
The surface plot depicts recrystallization times from 1 to 5 days. The maximum in the plot is 
observed at 61.25 wt.% XYL, 15.31 wt.% MAN, which corresponds to the eutectic composition. 
The composition also included 7.81 wt.% PEG 6000, and the PCT content of the pastille was 
15.63 wt.%. The calculations indicated that the pastille mass should be ~256 mg containing the 40 
mg of PCT.  In case of XYL–SORB pastilles we used 38.28 wt.% XYL, 38.28 wt.% SORB 
(which corresponds to the eutectic composition), 15.63 wt.% PCT and 7.81 wt.% PEG 2000 / 
6000, because PEGs had no significant influence on the eutectic concentration of sugar alcohols. 
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5.3.3. Viscosity measurements 
The viscosity of the melted dispersions is a critical parameter for drop formation. High 
viscosity decreases molecular mobility, and therefore hinders recrystallization. For our viscosity 
measurements, all the dispersions were melted on a heated magnetic stirrer, then the melt was 
thermostated on the plate of the viscosity measuring device. Measurements were carried out at a 
constant temperature of 110°C. All measurements were performed in triplicate and the average 
values are shown in Table 13. 
Table 13 Viscosity data of the compositions to be pastilled (n=3)  
Composition Viscosity (mPas) 
XYL-MAN-EUT 347±5 
XYL-MAN-EUT + PEG 6000 (7.81%) 352±6 
XIL-SORB-EUT 368±3 
XYL-SORB-EUT + PEG 2000 (7.81%) 370±20 
XYL-SORB-EUT + PEG 6000 (7.81%) 359±13 
The viscosity values of all samples were similar. The viscosity of the sample containing PEG 
2000 was slightly higher than that of the one containing PEG 6000. This phenomenon was 
unexpected because the viscosity of pure PEGs is known to increase with their molecular weight. 
To clarify this behaviour of the samples, viscosity measurements were expanded using other 
compositions containing PEGs in different ratios (5%, 7.81%, 10%, 15%, 20%, 30%, 60%, 
100%). Fig. 24 shows the viscosity of the different compositions.  
 
Fig. 24: Viscosity of XYL-SORB-EUT compositions containing different concentration of PEGs 
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It could be observed that the viscosity of pure XYL-SORB-EUT (368±3 mPas) and that of PEG 
6000 (370±2 mPas) are almost the same. According to these results, significant changes in the 
viscosity of eutectic and PEG 6000 compositions could not be expected. Even so, our results 
showed the viscosity curve has a minimum value under 20 % PEG 6000 concentration. PEG 2000 
has significantly lower viscosity than pure XYL-SORB-EUT, but the increase of the 
concentration of PEG 2000 in the composition led to the drastic decrease of the viscosity 
(Fig. 24). The viscosity changing effect of PEGs strongly depends on their molecular weight. 
Therefore in low PEG concentration PEG 2000 and 6000 containing samples show a similar 
viscosity value. 
5.3.4. Contact angle measurements 
 The wettability of the pastilles has a significant influence on the dissolution rates and the 
release characteristics in oral drug delivery. Wettability is characterized by the contact angle of 
the liquid (water). A smaller contact angle indicates greater wettability of the pastille. To 
formulate an appropriately dissolving pastille, a well-wetting surface is a fundamental step. The 
polarity percentage can be calculated from the interfacial tension of the polar component (γp), the 
interfacial tension of disperse component (γd) and the surface free energy (γ) (Table 14).  
Table 14 Contact angles (θ), surface free energies (γ) and polarities of compositions 
Compositions 
θwater 
(°) 
θdiiodomethane 
(°) 
γd 
(mN/m) 
γp 
(mN/m) 
γ 
(mN/m) 
Polarity 
(%) 
XYL-MAN-EUT 32.9±3.24 36.7±1.83 46.34 30.92 77.26 40.02 
XYL-MAN-EUT + 
PEG 6000 
34.7±1.79 44.3±2.58 38.21 32.47 70.68 45.94 
XYL-MAN-EUT + 
PCT + PEG 6000 
35.4±1.64 45.3±2.09 35.95 32.76 68.71 47.68 
XYL-MAN-EUT + 
PCT 
33.8±2.35 34.9±1.88 44.82 31.63 76.45 41.37 
XYL-SORB-EUT 28.1±3.6 20.5±2.9 42.96 31.74 74.70 42.49 
XYL-SORB-EUT + 
PEG 2000 
17.0±1.47 29.7±1.62 39.98 36.60 76.58 47.79 
XYL-SORB-EUT + 
PEG 6000 
21.6±3.63 19.5±2.72 43.22 34.03 77.25 44.05 
XYL-SORB-EUT + 
PCT 
26.7±4.71 22.7±1.84 42.33 32.49 74.82 43.24 
XYL-SORB-EUT + 
PCT + PEG 2000  
34.0±1.82 47.9±2.91 32.41 33.17 65.58 50.58 
XYL-SORB-EUT + 
PCT + PEG 6000 
30.1±3.40 35.9±1.45 37.62 32.77 70.39 46.55 
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The results show that the PEGs increase the surface free energies and the polarity of the 
compositions without PCT. PCT dissolves in the melt of the eutectic and recrystallizes during the 
solidification; it has no effect on the value of γ. In the case of the compositions with PCT, the 
PEGs (mainly PEG 2000) decrease γ and increase the polarity, which promotes the wetting of the 
pastille, therefore the dissolution. 
5.3.5. Pastillation of the carrier 
Pastillation took place on the surface of a thermostated cooling plate at 25 °C for 24 h. 
Because of the relatively high viscosity of the melt, the molecular mobility was decreased and 
crystallization was hindered in the core. PEGs do not prevent the recrystallization of the 
components, they were applied as softener material to form the pastille. In order to initiate 
crystallization, pure XYL crystals were used as seeds (Talja et al., 2001).  
 After 24 h a thin XYL shell crystallized on the surface of the pastille, which gradually 
thickened during the storage until the whole of the pastille had solidified. After 5 days the core 
was fully solid as shown previously by the surface plot (Fig. 24), but after 3 days the DSC 
analysis demonstrated that the crystallization of the sample was still taking place. Fig. 25 presents 
DSC curves of samples stored for various times. 
 
 
Fig. 25: Recrystallization of the XYL-MAN-EUT + PEG 6000 pastille carrier 
 
38 
 
The endotherms in the DSC curves indicate the melting temperature of XYL. The increasing area 
of the peaks reflects the extent of crystallization. As the crystallization progresses, the glass 
transition undergoes a depression. Table 15 shows the DSC data of recrystallization. 
 
Table 15 DSC data of recrystallization compared to physical mixture  
Time of measurement 
(h) 
Melting temperature 
(°C) 
Fusion enthalpy 
(J/g) 
24 88.59 12.47 
48 89.36 104.81 
72 90.50 123.16 
120 95.50 168.57 
Physical mixture 95.40 168.27 
 
We found that during the recrystallization of the XYL-MAN-EUT + PEG 6000 pastille, a phase 
separation occurs. A well-defined shell and core structure can be differentiated, therefore the 
phase separation was investigated with DSC (Fig. 26). 
 
Fig. 26: DSC curves of XYL-MAN-EUT + PEG 6000 pastille shell (A) and core (B) 
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The melting temperatures of the core and shell of the pastille are different. The melting 
temperature of the shell is at 97.6 °C parallel with the melting temperature of starting XYL. The 
melting temperature of the core structure is at 95.5 °C, which is parallel to the eutectic 
temperature of XYL-MAN.  It means the eutectic composition is located in the core of the 
pastille. 
5.4. Pastillation process with PCT 
 On the basis of the factorial design, for XYL-MAN containing pastilles 61.25 wt.% XYL, 
15.31 wt.% MAN, 7.81 wt.% PEG 6000 and 15.63 wt.% PCT (Fig. 23) were used and for XYL-
SORB containing pastilles 38.28 wt.% XYL, 38.28 wt.% SORB, 15.63 wt.% PCT and 7.81 wt.% 
PEG 2000/6000 (Fig. 27). This gave the best pastille shape without visible pores, and a 
homogeneous shell texture. The PEG content resulted in an appropriate crystallization time and 
decreased the melting temperature of the mixture through the formation of a solid dispersion 
(Akiladevi et al., 2011).  
 
Fig. 27: Steps of pastillation process 
After storage for 5 days, the pastille and the physical mixtures were investigated by DSC 
and compared. The DSC curves of the recrystallized pastille and the initial components can be 
seen in Fig. 28. 
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Fig. 28: DSC curves of pastilles and components, A: PCT, B: XYL-MAN-EUT + 
PEG 6000, C: XYL-MAN-EUT + PEG 6000 pastille, D: XYL-SORB-EUT + PEG 2000, E: 
XYL-SORB-EUT + PEG 6000, F: XYL-SORB-EUT + PEG 2000 pastille, G: XYL-SORB-
EUT + PEG 6000 pastille 
The DSC curves demonstrate that the high melting temperature of PCT (A), is not seen in the 
DSC curves of the physical mixture and the pastille (B to G), as a result of the PCT partly 
dissolving in the melt of the eutectic.  
5.4.1. X-Ray powder diffraction (XRPD) 
Because of the fusion of PCT in the eutectic, the possibility of polymorphic transition of 
the API during the recrystallization must be considered. PTC has three crystal modifications: a 
monoclinic form I, which has poor direct compressibility, an orthorhombic form II, and an 
unstable phase (form III), which can be stabilized only under certain conditions (for example, 
between a microscopy slide and a cover glass) (Perlovich et al., 2007). XRPD measurements were 
carried out to identify the polymorphic form of the PCT in the product. The comparison of the 
diffractogram of the starting PCT with the diffractograms of the various crystal modifications 
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available from the Cambridge Crystallography Data Centre (CCDC ID: AI631510) revealed that 
the starting PCT was in monoclinic Form I (Fig. 29A). The shell and core structures of the 
pastilles were investigated after 5 days by means of XRPD; the diffractograms are presented in 
Fig. 29B. 
 
 
Fig. 29: Diffractograms of the polymorphic forms of PCT and the starting components (A) in 
comparison with shell and core structure of pastilles (B) at different locations and in the 
presence of different PEGs 
 
The characteristic peaks of the components can be traced in the diffractograms of the 
pastille cores and shells. The characteristic peaks of the PCT in the core at 13.924° and 23.557° 2θ 
indicate the presence of the monoclinic form I. The XYL-MAN-EUT + PCT + PEG 6000 
contains XYL, MAN and PCT, the XYL-MAN-EUT + PCT + PEG 6000 core shows amorphous 
signs, but contains PCT crystals. The XYL-SORB-EUT + PCT shell contains PCT and XYL, and 
the characteristic peaks of SORB at 10.055° and 10.595° 2θ could not be detected. The 
diffractogram of the XYL-SORB-EUT + PCT core shows amorphous signs, but contains PCT 
crystals. From these results the homogenous distribution of PCT in the pastille could be supposed. 
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The XYL-SORB-EUT + PCT + PEG 2000 shell and XYL-SORB-EUT + PCT + PEG 6000 shell 
contain PCT and xylitol, and the characteristic peaks of SORB could also be detected. The XYL-
SORB-EUT + PCT + PEG 2000 core contains PCT crystals, but some amorphous signs could be 
detected. The diffractogram of the XYL-SORB-EUT + PCT + PEG 6000 core shows that the core 
structure is partly amorphous and contains SORB and PCT crystals. Since some characteristic 
peaks of the components overlap, we had to use Raman spectroscopy to locate the components. 
5.4.2. Raman spectroscopy 
Because of the slow solidification, the distribution of the PCT in the pastilles was first 
investigated by TRS. Figure 30 shows the transmission Raman spectra of pure PCT (a) and the 
XYL-MAN-EUT + PCT + PEG 6000 pastille shell (b) and core (c). The spectra in b and c are 
basically identical, the almost negligible differences involving new peaks due to the non-PCT 
ingredients. The pastille spectra indicated that there was no change in the crystal modification of 
the material in the sample tray during the measurement, with the main characteristic Raman bands 
of PCT in the intervals of 1660-1540, 1400-1160, 870-770 and 660-560 cm-1. The identity of 
spectra b and c confirmed the uniform distribution of PCT throughout the pastilles. 
 
Fig. 30: Transmission Raman spectra of the starting PCT (a), the shell of XYL-MAN-EUT + 
PCT + PEG 6000 pastille (b) and the core of the PCT containing pastille (c) 
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To identify the polymorphic forms of the PCT after the recrystallization, DRS spectra 
were acquired with a DXR instrument. The DXR Raman spectra of all the PCT forms produced in 
various modes of the heating-cooling process were identical and were those of the metastable 
orthorhombic polymorph of PCT form II (not shown). The Raman spectra of PCT display strong 
bands at 1648, 1610, 1561, 1323, 1236, 857, 796, 650 and 390 cm-1, assigned to -NH·CO·CH3 
stretching, C-C Ar stretching, C-N stretching / in-plane N-H bending, C-N stretching, phenyl-N 
and Ar C-C stretching, out-of-plane C-C skeletal deformation,  C-N-C stretching and Ar =C-H 
out-of-plane deformation, respectively (Fig. 30a). Table 16 lists the principal Raman bands of 
PCT, and selected Raman bands of MAN, PEG 6000 and XYL are presented in Fig. 31. Although 
most of the main and characteristic Raman bands of the ingredients and PCT overlap, the 
differentiation of the PCT is of primary importance. The highlighted Raman bands at 1660-1540, 
1168, 710 and 390 cm-1 were used to identify the PCT in the pastilles. 
Table 16 Observed Raman peaks and their assignments for the starting PCT, form II of PCT 
and for the PCT-containing pastille (shell and core) 
PCT PCT 
form II 
Pastille 
shell 
Pastille 
core 
Assignment 
464w 453w 465w 464w skeletal bending 
503m 508w 505w 505w Ar ring deformation 
650s 650s 652m 652m Ar =C-H out-of-plane deformation 
710m 709w 711w 711w out-of-plane CN-H and phenyl deformation 
796s 798m 798m 798m phenyl-N bending and out-of-plane p-substituted Ar ring 
deformation 
857vs 860s 858s 857s out-of-plane C-C skeletal deformation 
968w 966w 969w 970w C-C stretching 
1104w 1106w 1105w 1109w CH3 rocking 
1236s 1219m 1237s 1238m phenyl-N and Ar C-C stretching 
1256w 1244w 1257w 1257w symmetrical CH3 deformation 
1323s 1326vs 1324s 1324s C-N stretching 
1515w 1510w 1515w 1517w secondary amine deformation 
1561m 1560w-
sh 
1561m 1562w C-N stretching and in-plane N-H bending 
- 1575m - - amide N-H deformation 
1610s 1608s 1610s 1611s C-C Ar stretching 
1617vw-
sh 
1623s 1619sh 1619sh asymmetrical C=C Ar stretching, C-N stretching 
1648s 1648m 1648s 1648m -NH·CO·CH3 stretching 
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Fig. 31: DXR spectra of the starting PCT (a) and the components as MAN (b), PEG 6000 (c) 
and XYL (d) 
Fig. 32 presents DXR spectra of the starting PCT, form II and the PCT in the pastille shell 
and the core. The most marked differences between the two polymorphic PCT forms are to be 
seen in the highlighted regions, i.e. the intense Raman double peak at 1617-1610 cm-1 was split 
into two peaks at 1623 and 1608 cm-1 and one new peak appeared at 1575 cm-1, in parallel with a -
decrease in the intensity of the peak at 1560 cm-1. The PCT form II spectrum exhibits the 
characteristic peaks of the starting PCT, but shifted to higher wavenumber: as 15611575, 
13711374, 13231326, 857860, 833837, 503508 and 328330 cm-1. This indicates 
that the corresponding chemical bonds are in a higher energy state. Table 16 lists the principal 
Raman bands of PCT form II, the metastable physical state of this, having a higher energy state 
than that of the starting PCT, which is consistent with the reported data. The exceptions 
(12561244, 12361219 and 464453 cm-1), are attributed to the symmetric CH3 deformation, 
the phenyl-N and aromatic C-C stretching and the skeletal bending of PCT. The presence of PCT 
in the pastilles was not associated with the formation of the metastable PCT, form II. These data 
confirm the PCT is in the thermodynamically stable monoclinic form.  
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Fig. 32: DXR spectra of the starting PCT (a), form II of PCT (b), the shell of XYL-MAN-
EUT + PCT + PEG 6000 pastille (c) and core of the pastille (d) 
Fig. 33 shows the distribution map of different forms of PCT and XYL in one pastille at 
10* magnification. In order to confirm the homogeneity of PCT, the pastille mapping has been 
resolved. The characteristic bands obtained for different PCT polymorphs presented in Fig. 32 as 
highlighted regions have been used to visualize the spatial distribution of PCT from Raman 
chemical mapping. The resolution of the chemical map and therefore the identification of the 
ingredients present can be produced using multivariate curve resolution – alternating least squares 
(MCR-ALS) chemometric method. This method allows for the recovery of the response profiles 
of different components in complex samples, and provides information about the composition. 
Furthermore, this method is an enhancement over simple surface mapping analysis, since the 
qualitative and quantitative information are calculated at the same time. Unlike the principal 
components resulting from principal component analysis (PCA), the component spectra from 
MCR-ALS method can be compared directly to spectral databases. The purpose of the analysis 
was to confirm the homogeneous distribution of the PCT and xylitol in the pastille. According to 
the chemical mapping, in fact, PCT can be found in well-defined packages inside the pastilles, 
properly to the stratification of the pastille inner structure. The higher xylitol (marked in green 
colour) concentration of the pastille’s outer shell was also confirmed by Raman mapping. 
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Fig. 33: Raman distribution map of two PCT polymorphs (monoclinic PCT-blue, 
orthorhombic PCT-red) and xylitol (green) in one whole pastille (at 10* magnification). 
5.4.3. Geometrical parameters and hardness 
The diameter and the height of 20 pastilles were measured with a screw micrometer and 
their mass with analytical scales. The average diameter of the pastilles was 10.60±0.31 mm, the 
height was 3.11±0.23 mm and the mass was 279±2 mg mg. Fig. 34 illustrates the top view (A) 
and the largest vertical cross-section (B) of the drop-melted pastille. 
 
 
Fig. 34: The top view (A) and the largest vertical cross-section (B) of the drop-melted 
pastilles 
The braking hardness of 5 pastilles was measured. The average hardness of the pastilles 
made from XYL-MAN-EUT + PCT + PEG 6000 was 25±5 N, that from XYL-SORB-EUT + PCT 
was 29±5 N, that from XYL-SORB-EUT + PCT + PEG 2000 was 27 ±6 N and that from XYL-
SORB-EUT + PCT + PEG 6000 was 27±4 N.  
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5.4.4. Drug content determination 
Before the in vitro dissolution studies, the drug content of the pastilles was determined. 
Three different batches from each composition were investigated. The calculated and measured 
PCT contents of the pastilles were 40.19 mg, spectrophotometrically 40.12 ± 0.31 mg, 
respectively. 
5.4.5. In vitro dissolution studies 
In vitro dissolution studies of PCT containing pastilles after the total recrystallization (5 
days) were carried out. In three parallel measurements, the PCT dissolutions of the pastilles 
produced from different compositions were compared at the oral cavity pH (pH 6.8±0.1) and in 
the gastric juice (pH 1.2±0.1) (Figs 35 and 36). 
 
Fig. 35: Dissolution extents of drop-melted pastilles at the oral cavity pH of 6.8±0.1 and 
37±0.5 °C (average value±SD, n=3). 
In all cases, the PCT was practically fully dissolved from the pastilles in the medium of 
the oral cavity (pH 6.8±0.1) within 20 min.  
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Fig. 36: Dissolution extents of drop-melted pastilles at the gastric pH of 1.2±0.1 and 37±0.5 
°C (average value±S.D., n=3). 
In the acidic medium (pH 1.2±0.1) the PCT also practically fully dissolved within 20 min 
in the case of the PEG-containing pastilles. The pastille without PEG dissolved only after 30 min. 
The differences in the extents of dissolution can be explained by the different surface free 
energies of the pastilles. The lower surface free energy of the (PEG)-containing pastilles resulted 
in higher polarity and faster dissolution than in the case of the pastille without PEG. When the 
pastille is swallowed, the liberation of PCT also occurs, but 5 min longer is required than in the 
mouth. It could be concluded that, by using PEGs, the wettability and therefore the dissolution 
time of the pastilles were improved, which justified this dosage form. 
Summary 
This part of experimental work discusses the application of developed carrier system and 
the melt technology to have a PCT containing pastille as new lozenge dosage form for children 
therapy. The eutectic composition of XYL-MAN and XYL-SORB was first determined by 
constructing the binary phase diagram and the Tamman triangle from the DSC data. As a 
component of the carrier, PEG as a softener agent did not inhibit the recrystallization of the 
components but the solidification would be slower, which promoted the pastille forming. Contact 
angle measurements showed that wettability can be improved by using PEGs in the formulations. 
The viscosity changing effect of PEGs strongly depends on the molecular weight. It was revealed 
that solidification occurred in the pastilles and the shell especially consisted of XYL. The Raman 
measurement showed the homogenous distribution of components in the pastille.  
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6. CONCLUSIONS 
The aim of our research work was to apply conventional technologies such as spray-
drying and melt technologies with new approaches to research and develop innovative PCT 
containing solid DDSs for paediatric administration. The spray-drying process was applied to 
prepare microcomposites for dose sipping form and the melt process was suitable to formulate 
pastilles with “in situ coating” technology as lozenge.  
I.  First we surveyed the literature background of innovative forms used in paediatric therapy 
with conventional technologies, spray-drying and melt technology. In this part of work, the 
possibilities of innovation, the viewpoints of development of paediatrics, preparation methods and 
two innovative dosage forms were surveyed. Examples related to spray-drying and melt 
technology were collected. Finally, the pros and cons of the dose sipping form and lozenges were 
collected as “value added” preparations for “unmet medical need”. 
II. In the experimental part, two conventional technologies were applied to formulate 
different innovative DDSs in an organic solvent free manner for oral administration. One of the 
formulations was microcomposites produced with spray-drying, which can be applied as a dose 
sipping form. The other drug delivery systems were lozenges formulated with in situ coating 
technology.  These formulations did not contain any colouring agents or preservatives. 
III. The spray-dried TRE carrier was investigated with different screening methods. The 
investigation of spray-dried TRE suggested a method which is sensitive and rapid to predict the 
recrystallization process in the preformulation study. In this light, the suitable choice of the 
storage conditions can protect the amorphous TRE samples from crystallization. It could be 
concluded that HH-XRPD is faster than other conventional techniques and a good prediction for 
the recrystallization of amorphous compounds during preformulation, moreover, the physical 
changes could be studied on one sample. In view of these results, TRE was applicable for 
formulating API containing microcomposites with spray-drying.  
 Melt technology was the development of such crystalline drug carrier/basis for pastilles 
which consists of two-two well-recrystallized sugar alcohols and PEG as poor crystallization 
inhibitor. This carrier system is suitable for use in melt technology to formulate pastilles 
containing recrystallized PCT.  
IV. After the incorporation of a low amount of PCT in the forms, dosage form investigations 
were carried out. The investigation of microcomposites showed that the use of PEGs in the 
formulation decreased the electrostatic charge of the particles and produced good flow properties. 
Spray-drying resulted in amorphization in the samples (TRE, PCT), Tg could be determined, 
PEGs remained semicrystalline in the formulations. After 3 months the samples remain 
amorphous at ambient temperature and RH. In the pastilles solidification occurred after 5 days 
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and the shell consisted of mainly xylitol. The Raman measurement justified the homogenous 
distribution of the components in the pastille. The in vitro dissolution studies showed in the 
presence of PEGs the extent of PCT dissolution was higher than from the pure eutectic because of 
its lower surface free energy and higher polarity. 
V. All in all, we can conclude spray-drying and melt technology can be utilized in the 
industry for producing dosage forms without any organic solvents, colouring agents and 
preservatives, using natural excipients, which can be well tolerated e.g. in children’s therapy. 
Practical relevance and new approaches of this research work are the followings:  
1. Spray-drying and melt technology as conventional technologies are suitable to 
formulate different innovative DDSs in an organic solvent free manner, without any 
colouring- or preservative agents, avoiding lactose and sucrose, meeting the 
requirements of paediatric therapy. 
2. TRE based microcomposites made by spray-drying technology can be successful in 
development of amorphous DDS. 
3. Two sugar alcohols and PEG based DDSs result in new compositions for melt 
technology (in situ coating process). 
4. Suggested new formulations may be the PCT containing dose sipping form and 
pastilles as lozenge, which can be utilized in the industry for paediatric preparations. 
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A trehalóz, mint amorfizálódásra hajlamos segédanyag, 
rekrisztallizációjának vizsgálata
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Bevezetés
A gyógyszerformák tervezésénél a hatóanyagok 
mellett a segédanyagok is kulcsfontosságú szere-
pet töltenek be. A helyes segédanyag megválasztá-
sával jobb oldódási profil, nagyobb stabilitás, mó-
dosított hatóanyag leadás és jobb préselhetőség ér-
hető el [1]. Az iparban általában kristályos formá-
ban dolgozzák fel a ható- és segédanyagokat a for-
mulálás során, azonban egyes esetekben ked ve-
zőbb tulajdonságok érhetőek el az amorf forma 
alkalmazásával. Ezen tulajdonságok közé tartozik 
a jobb vízoldékonyság, jobb préselhetőség, ismé-
telt szabadalmaztathatóság és a polimorf módosu-
latok egymásba alakulásának megakadályozása 
[2]. 
A száraz porinhalációs készítményeket (Dry 
Powder Inhaler – DPI) leggyakrabban porlasztva- 
vagy fagyasztva szárítással állítják elő. Ezekkel az 
eljárásokkal kívánt szemcseméretű, valamint kivá-
Summary
Katona, G., Jójárt-Laczkovich, O., Szabó-Révész, P.*: Investiga-
tion of the recrystallization of trehalose as a good glass-
former excipient
An amorphous form of trehalose is easy to prepare by using a 
solvent method. The recrystallization kinetics can be followed 
well, which is important because of the occurrence of polymorphic 
forms of trehalose. This is especially significant in the case of dry 
powder inhalers. Spray-drying was used as a preparation meth-
od this being one of the most efficient technologies with which 
to obtain an amorphous form. This method can result in the re-
quired particle size and a monodisperse distribution with excel-
lent flowability and with moreover considerable amorphization. 
In our work, trehalose was applied as a technological auxiliary 
agent, and literature data relating to the spray-drying technology 
of trehalose were collected. Studies were made of the influence of 
the spraying process on the amorphization of trehalose and on the 
recrystallization of amorphous trehalose during storage. Amor-
phous samples were investigated under 3 different conditions 
during 3 months.  The recrystallization process was followed by 
differential scanning calorimetry and X-ray powder diffraction. 
The results demonstrated the perfect amorphization of trehalose 
during the spray-drying process. The glass transition tempera-
ture was well measurable in the samples and proved to be the same 
as the literature data. Recrystallization under normal conditions 
was very slow but at high relative humidity the process was accel-
erated greatly. Amorphous trehalose gave rise to dihydrate forms 
(γ- and h-trehaloses) during recrystallization, and β-trehalose 
was also identified as an anhydrous form. 
Keywords: trehalose, amorphous form, spray-drying, recrystal-
lization, polymorphism.
Összefoglalás
A trehalóz oldószeres eljárással könnyen amorfizálható anyag. 
A rekrisztallizáció folyamata jól nyomon követhető, vizsgálata 
pedig indokolt a spontán amorfizálódás következtében megjele-
nő különböző polimorf módosulatok miatt. Ennek különösen a 
porinhalációs készítményeknél van jelentősége. Oldószeres eljá-
rásként a porlasztva szárítást alkalmaztuk, amivel kívánt szem-
cseméretű, kiváló folyási tulajdonsággal rendelkező monodiszperz 
rendszer állítható elő, valamint nagymértékű amorfizálódás kö-
vetkezhet be. A kísérletes munka előzményeként bemutatjuk a 
trehalózt, mint a gyógyászatban alkalmazott segédanyagot és 
annak legfontosabb tulajdonságait, illetve porlasztva szárítással 
történő feldolgozásának irodalmi hátterét. Arra kerestük a vá-
laszt, hogy porlasztva szárítással előállítható-e amorf trehalóz, 
s különböző körülmények között tárolva (3 hónap), milyen vál-
tozásokat tapasztalunk. Analitikai módszerként a differenciális 
pásztázó kalorimetriát és a porröntgen diffrakciós módszert alkal-
maztuk. Megállapítottuk, hogy a porlasztva szárítás nagymérté-
kű amorfizálódást okoz a mintákban. Az üvegesedési hőmérséklet 
mérhető és az irodalmi értékkel megegyező tartományba esik. To-
vábbá megállapításra került, hogy magas páratartalmú közegben 
a trehalóz túlnyomórészt dihidrát formában (γ- és h-trehalóz) 
kristályosodik vissza, és a rekrisztallizáció üteme lényegesen fel-
gyorsul. A rekrisztallizáció során egyéb polimorf módosulatot is 
azonosítottunk (anhidrát β-trehalóz). 
Kulcsszavak: trehalóz, amorf forma, porlasztva szárítás, 
rekrisztallizáció, polimorfia
2 Acta Pharmaceutica Hungarica 2014/1.
ló folyási tulajdonsággal rendelkező monodisz­
perz rendszer állítható elő, viszont nagymértékű 
amor fizálódást is eredményezhet. A folyamatot, 
amikor az anyag valamely gyártásközi művelet, 
esetleg a tárolás során részben vagy egészben 
amorfizá lódik, „indirekt amorfizálásnak”, vagy 
amorfizáló dás nak nevezzük. A kristályos és az 
amorf forma aránya a porinhalációs készítmények 
alkalmazhatóságát jelentősen befolyásolja, így fo-
lyamatos kontrollálást igényel mind a gyártás, 
mind pedig a felhasználásig történő tárolás során.
A kísérletes munka modell segédanyaga
A kísérletes munka modell anyagának a trehalózt 
választottuk, mint amorfizálódásra hajlamos se-
gédanyagot, mivel a feldolgozás során könnyen 
amorfizálódhat. A trehalóz α­D­glükopiranozil­α-
D­glükopiranozid–dihidrát (α,α-trehalóz–dihid-
rát) vagy mikóz, ami egy természetes alfa­kötésű 
diszacharid, amelyet két α­glükózegység alkot α 
1→1 glikozidos kötéssel (1. ábra). Fehér, vagy 
csaknem fehér kristályos por, amely vízben bősé-
gesen, metanolban alig és etanolban gyakorlatilag 
nem oldódik.
A trehalóz a természetben is előforduló anyag. 
Gombák (ebből adódik egyik szinoním neve, a 
mikóz = „gomba cukor”), növények és gerinctelen 
állatok is bioszintetizálják. Széles körben alkal-
mazzák segédanyagként az ipar több területén is, 
mint például a kozmetikai‑, mezőgazdasági‑, élel-
miszer‑ és a gyógyszeriparban. Az iparban a ke-
ményítő enzimatikus átalakításával állítják elő. 
Más diszacharidoktól eltérően, az előállítás folya-
mán nem lép kémiai reakcióba aminosavakkal 
vagy fehérjékkel, és ez megakadályozza a termék 
barnulását (Maillard reakció). A trehalóz egy nem 
reaktív cukor. Erős stabilitása a két glükopiranóz 
gyűrűt összekötő glikozidos kötés kis energiájá-
nak (1 kcal/mol) köszönhető. Nem disszociál két 
redukáló monoszacharid 
alkotórészre, csak extrém 
hidrolitikus körülmények 
között vagy tre haláz en-
zim hatására (amelyet a 
gombák és az emberi 
szervezet is szintetizál).
Szerepet játszik a növé-
nyek és állatok anhid ro‑
biózisában, vagyis abban 
a tulajdonságukban, hogy 
hosszú ideig képesek 
életben maradni víz nél-
kül. Nagy víztartó képességét a kozmetikai‑ és 
élelmiszeriparban is hasznosítják.
A biomolekula stabilizációjának mechanizmusát 
először Fourier‑transzformációs infravörös spekt-
roszkópia (FT‑IR) alkalmazásával vizsgálták a fe-
hérjék és cukrok közötti kölcsönhatások jellemzésé-
nek céljából. Ezt követően infravörös (IR) és Ra‑
man‑spektroszkópia segítségével kimutatták, hogy 
a trehalóz legjelentősebb funkciója, hogy koncent-
rálja azt a kis mennyiségű vizet a fehérje közelében, 
amely a funkció megtartásához szükséges. A tre‑
halóz fehérjestabilizáló képességét az ipar számos 
területén hasznosíthatják; például a kozmetikai 
iparban hidratáló készítményekben, vagy a gyógy-
szeriparban liposzóma stabilizálására.
Az élelmiszeriparban szintén alkalmazott se-
gédanyag. Itt édesítő‑ és stabilizáló szerként egy-
aránt használják. Édessége a szacharóz 45%‑ával 
egyezik meg.
A gyógyászatban hatóanyagként is felhasználás-
ra kerül. „Chaperone” elnevezésű anyagként hasz-
nálják, amely segítséget nyújt a Creutzfeld–Jacob 
kórt, cisztás fibrózist és amiloid rendellenességeket 
okozó fehérje aggregációjának megelőzésében.
A trehalóz segédanyagként való legfontosabb 
alkalmazási területei gyógyszerészeti szempont-
ból az oltóanyagok stabilizálása szobahőmérsékle-
ten való tárolás céljára, enzimek tartósítása, illetve 
emlős sejtek liofilizálás alatti károsodástól való vé-
delme. Mivel koncentrálja a fehérje közelében a 
vizet, így az a liofilizálás után vissza tud rende-
ződni natív szerkezetébe és visszanyeri funkcióját. 
Fejlődő országokban a járványos gyermekbénulás 
ellen alkalmazott orális oltóanyagok előállításánál 
azt tapasztalták, hogy trehalóz jelenlétében 45 °C‑
on szárítva azok stabilak maradtak, összehasonlít-
va a 4 °C‑on lefagyasztott folyékony oldattal [3]. A 
trehalóz másik fontos alkalmazási területe a DPI 
formában történő hordozóanyagként való felhasz-
nálása [4‑6].
A trehalóz is, mint nagyon sok más a gyógy‑
szer technológiában alkalmazott ható‑ és segéd-
anyag, polimorfiára hajlamos. A segédanyagok 
polimorfiájának nagy jelentősége van a gyógy-
szeriparban, hiszen ez alapvetően meghatározza 
az adott forma olvadáspontját, oldékonyságát, fi-
zikai és kémiai stabilitását. A trehalóznak 4 poli-
morf módosulata ismeretes, amelyek különböző 
olvadásponttal rendelkeznek (I. táblázat) [7].
A fent említett példák azt támasztják alá, hogy a 
trehalóz, mint gyógyszertechnológiai segédanyag, 
számtalanszor kerül feldolgozásra porlasztva‑ [4, 
8‑10] és fagyasztvaszárítással [11‑13]. Mivel ezek 
1. ábra: Trehalóz (D(+)-
trehalóz-dihidrát) 
szerkezeti képlete
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az eljárások gyakran okoznak amorfizálódást, 
ezért a segédanyag ilyen szempontból történő 
vizsgálata igen érdekes lehet. Forgalomban lévő li-
ofilezéssel formulált védjegyzett készítmény pél-
dául az ADVATE®, amelyben a hatóanyagot, a 
rekombináns VIII‑as véralvadási faktort, a trehalóz 
stabilizálja [14]. Továbbá a 4 polimorf módosulat 
létezése a rekrisztallizáció követését is indokolja. 
Az amorfizálás technológiai megvalósítása
Az amorf anyagok kialakulására / kialakítására 
három technológia alkalmazható: olvadék technoló-
gia, őrléses és oldószeres eljárások [15]. Olvadék tech-
nológiával két úton lehet amorf anyagot előállíta-
ni. Az egyik művelet során a kristályos anyagot 
megolvasztjuk, majd ezt az olvadékot hirtelen der-
mesztjük. A másik művelet során a kristályos 
anyagot a segédanyag olvadékában diszpergáljuk, 
majd ezt az olvadékot szintén dermesztjük [16]. 
Dezintegráló műveletek közül őrléssel is előállít-
hatunk amorf anyagot. Őrlés során olyan mértékű 
mechanikai erőt fejtünk ki a kristályrácsra, amek-
korát az az elasztikus határok közt nem képes to-
lerálni, így megváltozik a szerkezete. A keletkező 
hő hatására a lokális olvadások miatt is amorfi‑
zálódhat az anyag [17]. Az oldószeres eljárások kö-
zött három csoportot különíthetünk el: hőmérsék-
letemeléssel történő dehidráció, nyomáscsökken-
téssel történő szárítás (liofilezés) [18], porlasztásos 
technológia [19]. Jelen munka az oldószeres megol-
dások témakörét, azon belül is a porlasztva szárí-
tást érinti.
Porinhalációs készítmények formuláláshoz  
alkalmazott segédanyagok 
gyógyszertechnológiai vonatkozásai
A porlasztva szárítás egyik jelentős felhasználási 
területe a por inhalációs készítmények előállítása. 
A porinhalációs rendszerek pulmonális gyógy-
szerbevitelre alkalmas szilárd fázisú készítmé-
nyek. Fő előnyük, hogy nagy koncentrációjú ható-
anyagot juttathatunk célzottan a tüdőbe és mini-
mális az extrapulmonális veszteség. Kiválthatunk 
vele helyi illetve szisztémás hatást, valamint ked-
vező a biológiai hasznosíthatósága. Ennek a 
gyógyszerformának a fejlesztése, relatíve kevés se-
gédanyaggal megoldható, a hatóanyag stabilitásá-
nak biztosítása egyszerű. Nincs hajtógáz, csupán 
egy adagolócsavar, melynek kattanásig történő te-
kerésével a „unit dose” adagolás biztosított, így 
nem kell tartani a túladagolástól sem [20]. A szem-
cseméretnek 1-5 μm-es mérettartományba kell es-
nie, mivel az ennél nagyobb szemcsék nem jutnak 
át a légutakon az alkalmazás helyére, az ennél ki-
sebbek pedig a kilégzéssel távoznak. Ahhoz vi-
szont, hogy a por jó folyási tulajdonságokkal ren-
delkezzen, ne legyen kohezív és jól lehessen dozí-
rozni, segédanyagokra van szükség. Ezeket az 
anyagokat, amelyek a hatóanyagot célba juttatják, 
hordozóanyagnak hívjuk. Erre általában α-laktóz-
monohidrátot alkalmaznak, de az új készítmé-
nyekben már más segédanyagokkal is helyettesít-
hetik a laktózt. Ennek egyik oka a TSE (átadható 
spongiform enkefalopátiás betegségek) elkerülése, 
a másik pedig, hogy a laktóz reakcióba léphet az 
amino csoporttal, így fehérje és peptid készítmény 
nem formulálható vele. Ebben az esetben a laktózt 
többek között trehalózzal helyettesítik. Lehetőség 
van még a raffinóz és a szukróz alkalmazására is. 
Ezeknek a nem redukáló cukroknak van egy 
olyan közös kedvező tulajdonsága, hogy porlaszt-
va szárítás során megvédik a fehérjéket vagy 
peptideket a különböző stresszhatásokkal szem-
ben. Helyettesítik a hidrogén kötéseket, amelyeket 
normál esetben a víz tesz, valamint viszkózus ke-
veréket alkotnak a fehérjével, melynek következ-
ményeként magas üvegesedési hőmérsékletű ter-
mék keletkezik [21].
Kísérletes munka
A kísérletes munkánk arra világít rá, hogy a poli-
morfiára hajlamos amorfizált vagy amorfizálódott 
segédanyagok a hőmérséklet és a relatív páratarta-
lom viszonyának változására különböző polimorf 
módosulatok formájában kristályosodhatnak visz-
sza és ennek nagy jelentősége van a feldolgozás, 
valamint az alkalmazás során. Mivel a Szegedi Tu-
dományegyetem Gyógyszertechnológiai Intézeté-
ben már van tudományos előzménye az anyagok 
amorfizálhatóságának [15, 22‑26], így azt a célt tűz-
tük ki magunk elé, hogy a porinhalációs készítmé-
nyek egyik fontos komponensének a trehalóznak, 
az amorfizálódását és az amorf forma tárolás so-
rán bekövetkezett rekrisztallizációját, polimorf 
módosulatait tanulmányozzuk.
I. táblázat 
A trehalóz polimorf módosulatainak olvadáspontja [7]
Polimorf módosulat neve Olvadáspont (°C)
α-trehalóz 126
β-trehalóz 215
γ-trehalóz 118-122
h-trehalóz 100-110
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Kiindulási segédanyag
A kiindulási anyag a D(+)‑trehalóz‑dihidrát volt 
(Carl. Roth. GmbH + Co. KG. 76185 Karlsruhe). Ezt 
tekintettük 100%‑os kristályos anyagnak. Víztar-
talma 9,5±0,5%, szulfáttartalma pedig kevesebb, 
mint 0,5% volt. Fajlagos forgatóképessége: 178±2°.
Minták előállítása
A kísérletes munkánk során két mintát állítottunk 
elő, azonos körülmények között. Mindkét esetben 
a trehalózból tisztított vízzel 10%‑os oldatot készí-
tettünk mágneses keverő segítségével, és ezt az ol-
datot BÜCHI B‑191 Mini Spray Dryer (Büchi, 
Svájc) készülékkel porlasztottuk a II. táblázatban 
megadott paraméterek mellett [10]. Az így nyert 
terméket szobahőmérsékleten (25±2 °C) exszikká-
torban tároltuk 32±5%‑os relatív páratartalmú 
(RH) légtérben a vizsgálatok indításáig.
Tárolási körülmények
A mintákat 3 hónapig tároltuk, különböző körül-
mények (hőmérséklet, relatív páratartalom‑RH) 
befolyását vizsgálva [27]. Az első porlasztott min-
tát (I) normál körülmények közt tároltuk, míg a 
másodikat (II) két részre osztottuk, egyik felét a 
gyorsított stabilitási vizsgálatoknak (IIa), másik 
felét pedig ennél intenzívebb terhelésnek (IIb) ve-
tettük alá, a következők szerint:
 ‒ normál körülmények között (I), exszikkátorban, 
25±2 °C és 32±5% RH,
 ‒ a gyorsított stabilitási vizsgálat körülményei kö-
zött (IIa), 40±2 °C, 75±5% RH [26],
 ‒ intenzíven terhelt kondíciók között (IIb), 
60±2 °C, 90±5%.
Utóbbi kettőnél mi állítottunk elő különböző 
koncentrációjú kénsav tartalmú higrosztát töltete-
ket és termosztátba helyeztük azokat. A tárolási 
körülményeket folyamatosan kontrolláltuk.
Vizsgáló módszerek
A mintákat METTLER Toledo 821e DSC (Mettler‑
Toledo GmbH., Gießen, Németország) segítségével 
vizsgáltuk. Ennek a módszernek a segítségével 
igazoltuk a trehalóz amorf formájának létét és az 
amorf forma üvegesedési hőmérsékletét (Tg) is kö-
vetni tudtuk a rekrisztallizációs folyamat során. A 
mérés során 5±0,2 mg mintát mértünk alumínium 
tégelybe analitikai mérleg segítségével, majd a té-
gelyt lezártuk és behelyeztük a kemencébe. A ke-
mencét 25 °C‑tól 250 °C‑ig fűtöttük fel 10 °C/min 
fűtési sebességgel és mértük a mintában lejátszó-
dó termikus változásokat. Az eredményeket 
STARe szoftver segítségével értékeltük ki. 
A visszakristályosodás folyamatának meghatá-
rozásához porröntgen diffrakciós vizsgálatokat is 
végeztünk. Erre Bruker D8 Advance diffrak to­
méterrel (Bruker AXS GmbH., Karlsruhe, Német-
ország) berendezést használtunk. Sugárforrásként 
Cu KλI sugárzást (λ= 1.5406 Å) alkalmaztunk. A 
minták vizsgálata 40 kV feszültség és 40 mA áram-
erősség alkalmazása mellett 3°­tól 40°­ig (2θ) tör-
tént. A szkennelési sebesség 0,1°/min, a lépésköz 
pedig 0,010° volt. A műszer kalibrálása korund se-
gítségével történt. Az eredmények kiértékelésére 
pedig DIFFRACTplus EVA szoftvert alkalmaz-
tunk. A diffraktogramokat Kα2-vel korrigáltuk, si-
mítottuk és az alapvonal korrekcióját is elvégez-
tük. A termékek azonosítására a Cambridge­i 
Krisztallográfiai Adatbázist (CCDC ID: AI631510) 
használtuk.
Differenciális pásztázó kalorimetriás  
vizsgálatok (DSC)
A trehalóz Tg–je kísérletes úton, DSC vizsgálattal 
meghatározható. A mintát felfűtöttük olvadás-
pontja fölé, majd visszahűtöttük szobahőmérsék-
letre és megismételtük a fűtést ugyanazzal a fűtési 
sebességgel. A következőket tapasztalatuk:
 ‒ a második melegítés során eltűnt a karakterisz-
tikus olvadáspont,
 ‒ a fűtési folyamat során nem érzékeltünk bom-
lásra utaló jelet,
 ‒ a Tg láthatóvá vált a görbén (2. ábra).
Az átmenet 109,3‑130,0 °C‑ig tart, középértéke 
115,4 °C‑nál található.  A trehalóz irodalomból ismert 
Tg‑je szintén ebben a tartományban található [7].
Irodalomból ismeretes, hogy az üvegesedési hő-
mérséklet és az olvadáspont hányadosa előrevetít-
heti az anyag amorfizálhatóságát [25]. A 3. ábrán 
látható, hogy a kiindulási trehalóz három poli-
II. táblázat 
Porlasztási paraméterek
Paraméterek Beállítás
Bemenő hőmérséklet (°C) 130-140
Kimenő hőmérséklet (°C) 75-92
Pumpaáramlás (ml/min) 2
Sűrített levegő nyomása (bar) 4,8
Atomiser pumpaáramlás (normoliter/h) 600
Aspirátor (%) 80
Pumpa áramlása (%) 2
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morf keveréke (A görbe). A görbe alatti terület ará-
nyos az egyes módosulatok mennyiségével. Leg-
nagyobb arányban a h-trehalóz található meg és ez 
a legjobban amorfizálható módosulat, Tg/Tm (K/K) 
értéke 1,03. Szintén jól amorfizálható a legkisebb 
mennyiségben előforduló γ-trehalóz, Tg/Tm (K/K) 
értéke 0,98. A legkisebb Tg/Tm (K/K) értékkel a 
β-trehalóz rendelkezik (0,71), de még ez a polimorf 
is a jól amorfizálható kategóriába esik. Ezen elő-
vizsgálatok alapján tehát megállapítható, hogy a 
trehalóz amorf formája állítható elő porlasztva 
szárítással és igazolást nyert az is, hogy a trehalóz 
valóban jól amorfizálható segédanyag. 
Az első porlasztásból (I) származó minta vizs-
gálati eredményeit szintén a 3. ábra szemlélteti. 
Az A görbén a kiindulási kristályos trehalóz látha-
tó, három polimorf módosulat különíthető el rajta. 
A három csúcs tehát a különböző polimorf módo-
sulatok olvadáspontja. A többi, B, C, D, E és F gör-
bék pedig a porlasztott minta DSC görbéi időrendi 
sorrendben. A mintákat normál körülmények kö-
zött tároltuk (25±2 °C, 32±5% RH), és másfél hóna-
pon keresztül vizsgáltuk. A B görbén a frissen por-
lasztott minta látható. Megállapítható, hogy a por-
lasztás nem eredményezett 100%-ban amorf ter-
méket, a minta némi kristályos frakciót tartalma-
zott, mégpedig a γ-trehalóz (dihidrát) polimorf 
módosulatot, amelynek 122 °C­nál van az olvadás-
pontja. Két nappal később vizsgálva láttuk a C gör-
bén, hogy a kristályos frakció nőtt, azaz megindult 
egy lassú rekrisztallizációs folyamat. Tizennégy 
nappal a porlasztás után azt tapasztaltuk a D gör-
bén, hogy megjelent egy másik polimorf módosu-
lat, a β­trehalóz (anhidrát), melynek 215 °C­nál 
van az olvadáspontja. Harminc (E), majd negyven-
két (F) nappal a porlasztás után azt a következte-
tést vontuk le, hogy mindkét polimorf módosulat-
hoz tartozó csúcs alatti terület nőtt, azaz nőtt a 
kristályos frakció mennyisége. 
Újabb sarzsot porlasztottunk (II) azonos körül-
mények között a trehalóz vizes oldatából. Az ezen 
porlasztásból származó minták vizsgálati eredmé-
nyeit mutatja a 4. és az 5. ábra. 
A 4. ábrán az A görbe a kiindulási kristályos 
trehalóz DSC görbéje. A B és C görbe pedig a friss 
és tárolt porlasztott mintáé. Látható, hogy nem 
eredményezett 100%-ban amorf terméket a máso-
dik porlasztás sem, a γ-trehalóz (dihidrát) poli-
morf módosulat megtalálható benne, olvadáspont-
ja 123 °C­nál található. A minták egyik felét 
40±2 °C, 75±5% RH higrosztát töltetben tároltuk és 
2. ábra: A trehalóz üvegesedési hőmérsékletének (Tg) 
meghatározása DSC módszerrel
3. ábra: Porlasztva szárított trehalóz rekrisztallizációjának 
DSC vizsgálata (I minta, tárolási körülmények: 25±2° C, 
32±5% RH). A: kiindulási kristályos trehalóz, B: friss 
porlasztott minta, C: két napos minta, D: tizennégy napos 
minta, E: harminc napos minta, F: negyvenkét napos minta.
4. ábra: Kiindulási, frissen porlasztott és tárolt minták 
DSC görbéje: a gyorsított stabilitási vizsgálatok (IIa) 
körülményeinek (40±2 °C, 75±5% RH) hatása az amorf 
trehalózra. A: kiindulási kristályos trehalóz, B: friss 
porlasztott minta, C: tárolt minta 7 nap után.
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hét nap után vizsgáltuk. A C görbén látható, hogy 
egy új polimorf módosulat jelent meg a β-trehalóz 
(anhidrát), 212 °C­nál. Következtetésként levon-
tuk, hogy a gyorsított stabilitási vizsgálat körül-
ményeinek hatására a minták 100%-ban vissza-
kristályosodtak, mégpedig a h-trehalóz (dihidrát) 
polimorf módosulatába, melynek olvadáspontja 
102 °C­nál található.
A 5. ábra mutatja a porlasztott minta rekrisz‑
tallizációs viselkedését szélsőséges körülmények 
között. Az A, B, C görbék szintén a kiindulási kris-
tályos trehalóz és a friss és a tárolt porlasztott 
minták DSC görbéi. A tárolási körülmények ennél 
a vizsgálatnál a következőképpen alakultak: 
60±2 °C‑on, 90±5% RH, tárolási idő: 7 nap. Ugyan-
azt tapasztaltuk, a kiindulási kevés kristályos 
frakciót tartalmazó amorf mintánk hét nap eltelté-
vel az agresszív tárolási körülmények hatására 
100%‑ban visszakristályosodott a h‑trehalóz (di‑
hidrát) polimorf módosulatába.
A DSC vizsgálatok eredményeit a III. táblázat 
foglalja össze. Megjelöltük, hogy a vizsgálatok so-
rán az irodalomban fellelhető trehalóz polimorf 
módosulatok közül, melyeket találtuk meg a min-
tákban. A DSC vizsgálatokból nyerhető adatok 
alapján, a minták adott polimorfra vetített kristá-
lyosságát is kiszámoltuk és jelöltük a táblázatban. 
Ez az eredmény félkvantitatívnak tekinthető, de a 
rekrisztallizációs tendencia leírására alkalmas. A 
vizsgálatok végén tapasztalt 100% fölötti értékek 
csupán a módszer félkvantitatív jellegére utalnak.
Porröntgen diffrakciós vizsgálatok (XRPD)
A porröntgen diffrakciós vizsgálatok eredményei 
összhangban vannak a DSC mérésekkel, amelyek 
a 6. ábrán lévő diffraktogramokon jól követhetők. 
Az ábra jól mutatja, hogy az A jelzésű kiindulási 
trehalóz kristályos termék, a B pedig az porlaszt-
va szárítás során képződött I. minta, amely röntgen 
amorfnak tekinthető.
Az újabb (II. minta) XRPD eredményeit a 7. ábra 
szemlélteti. Az A diffraktogram a kiindulási kris-
tályos trehalóz, a B a frissen porlasztott amorf 
minta és a C pedig a tárolt minta diffraktogramja. 
A B görbe kisimult, a jellemző intenzitás értékek el-
tűntek, azaz röntgen amorf terméket eredménye-
zett a porlasztás. A visszakristályosodó mintában 
(C) kezdenek megjelenni a karakterisztikus csú-
csok, összehasonlítva a Cambridge‑i Krisztallo-
gráfiai Adatbázisban lévő trehalóz dihidrát poli-
morf módosulat diffraktogramjával, látható, hogy 
5. ábra: Kiindulási, frissen porlasztott és tárolt minták  
DSC görbéi: szélsőségesen (IIb) terhelt (60±2 °C,  
90±5% RH) körülmények hatása az amorf trehalózra.  
A: kiindulási kristályos trehalóz, B: friss porlasztott minta, 
C: tárolt minta 7 nap után.
6. ábra: Kiindulási anyag és porlasztva szárított termék 
porröntgen diffraktogramjai: A: kiindulási kristályos 
trehalóz, B: friss porlasztott minta.
7. ábra: A kiindulási és porlasztással előállított 
minták porröntgen diffraktogramjai: amorf trehalóz 
rekrisztallizációja és a visszanyert anyag azonosítása.  
A: kiindulási kristályos trehalóz, B: frissen porlasztott 
minta, C: normál körülmények között (25±2 °C és  
32±5% RH) tárolt 1 napos minta.
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a jellemző csúcsok egybeesnek. A porlasztott ter-
mék tehát a trehalóz‑dihidrát polimorf módosu-
latba kristályosodik vissza. A kiindulási kristályos 
trehalózról (A) pedig megállapítható, hogy több 
polimorf módosulat keveréke, a módosulatok ref-
lexiói megjelennek a diffraktogramon.
Összefoglalás
A kísérletes munka során porlasztva szárítással 
állítottunk elő trehalóz oldatból amorf szilárd fá-
zisú terméket, majd vizsgáltuk a rekrisztallizáció 
folyamatát különböző körülményeket alkalmazva 
a tárolás során. Megállapítottuk, hogy a trehalóz 
porlasztva szárítással amorfizálódik (kevés kristá-
lyos frakció marad a rendszerben). A Tg mérhető a 
mintákban és megegyezik az irodalmi értékkel. 
Láthattuk, hogy viszonylag alacsony páratartalom 
mellett megindul a rekrisztallizáció, de a teljes fo-
lyamat igen lassú, időtartama hónapokban mérhe-
tő. Intenzívebb körülmények hatására viszont rob-
banásszerűen megindult a visszakristályosodás. 
A trehalóznál a dihidrát forma (γ- és h-trehalóz) a 
meghatározó a rekrisztallizáció során, de anhidrát 
forma (β­trehalóz) is detektálható. Megfelelően 
hosszú idő után a kiindulásival megegyező poli-
morf módosulatok keveréke nyerhető vissza. Ez 
azt támasztja alá, hogy azoknál a porinhalációs 
készítményeknél, ahol trehalóz a hordozó, külö-
nös figyelmet kell fordítani a megfelelő tárolási 
körülmények megválasztására.
„A kutatatás a TÁMOP‑4.2.2.A‑11/1/KONV‑
2012‑0035 Környezeti tényezők és genetikai faktorok 
interakciójának vizsgálata immunmediált és daganatos 
betegségek kialakulásába című kiemelt projekt keretében 
zajlott.”
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Abstract The focus of this work was to apply melt
technology for the formulation of a pastille containing
paracetamol (PCT) in a solid dispersion with two sugar
alcohols (xylitol and mannitol) and polyethylene glycol
6000 (PEG) as the carrier system components. Optimiza-
tion of the pastillization was performed both statistically by
using the Box–Behnken design and experimentally by
determining the phase diagrams. For the latter and
recrystallization of the components, differential scanning
calorimetry detection was utilized. The developed pastilles
consisted of a eutectic mixture of xylitol (61.25 %) and
mannitol (15.31 %) with PEG (7.81 %) as carrier system
together with PCT (15.63 %). The components of the
pastilles underwent recrystallization at different rates for
5 days. Transmission Raman spectroscopy revealed the
homogeneous distribution of the PCT in the pastille. X-ray
powder diffractometry showed that the recrystallization of
the PCT resulted in its monoclinic form I, while dispersive
Raman spectroscopy detected both the monoclinic and
orthorhombic forms. The drop-melted pastilles displayed
relatively high hardness, and the PCT dissolved within
15 min. It is concluded that pastillization can be achieved
through melt technology and the structure and the tech-
nological parameters of the pastille are suitable for the
development of lozenges as a solid dosage form for chil-
dren therapy.
Keywords Eutectic mixture  Sugar alcohols  Melt
technology  Paracetamol  Pastilles
Introduction
Melt technology is an increasingly used technological
operation in the pharmaceutical industry, whereby novel
products can be produced efficiently. This is a green
technology, involving dust-free processes, and elastic
materials can also be used to produce the final form. There
is no need for the use of extra organic solvents in the
production, and there are therefore no residual solvents in
the product and less environmentally harmful chemical
waste, in contrast with other conventionally used tech-
niques. Melt technology can result in amorphous products,
which may have higher dissolution rates and bioavailability
than those of the corresponding crystalline forms [1–5].
With a fusion method, a solid dispersion of the excipients
and active agent can be prepared. Through a drop-melting
method, pastilles can be formed, and pastillization is
achieved in one step of a conventional melting process.
New approach in this topic is a coating process during the
pastillization developed by Ulrich et al. [6–8], which
means the formation of a ‘‘coating material’’ via the phase
separation of a eutectic mixture.
In the USA, a buccal pharmaceutical preparation,
Meltaways (Tylenol), containing 80 mg of paracetamol
(PCT), is available as a chewable tablet in paediatric
therapy. Such solid preparations have the aim of fast
release. Although they are most often used for a localized
effect in the mouth, they can also be used for a systemic
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effect if the drug is well absorbed through the buccal lining
or is swallowed. Analgetics and antihistamines are com-
monly utilized in such formulations, which are easy to use
in paediatric or geriatric therapy, and the drug can be kept
in contact with the oral cavity for an extended period of
time. By means of buccal absorption, the disadvantages of
peroral administration can be avoided, such as the hepatic
first-pass metabolism or enzymatic degradation within the
gastrointestinal tract, which prevent the oral administration
of certain classes of drugs, particularly proteins and pep-
tides [9], and additionally, a lower amount of drug is
needed to achieve the therapeutic effect.
During hot-melt techniques, pharmaceutical auxiliary
agents such as polyethylene glycols (PEGs) or
polyvinylpyrrolidone [10] have often been applied as
meltable carriers [11, 12]. Besides PEGs, sugar alcohols
are also commonly used to prepare solid dispersions [13].
Sugar alcohols have a number of beneficial properties: they
often increase the dissolution of the dosage form, they
serve as masking agents, and they are suitable for diabetic
patients in view of their low glycaemic indices. b-D-Man-
nitol and D-xylitol are sugar alcohols that are often used in
the pharmaceutical industry. Both are stable and inert
compounds suitable for tableting, freeze-drying, capsuliz-
ing, granulating and grinding [14, 15] and as carriers in
pulmonary drug delivery systems [16].
Sugars and sugar alcohols form eutectic mixtures with
each other in certain ratios, resulting in a system with a
lower melting temperature than that of either of the com-
ponents [17]. The literature examples of this type include
mannitol–sorbitol [18], xylitol–isomalt [6] and xylitol–
sorbitol [19]. For xylitol–mannitol, we found eutectic
melting temperature [21], but the literature has not any
experimental work with this composition. Eutectics are
commonly used in drug designing and delivery processes.
Simple eutectic mixtures are solid dispersions involving
one or more active pharmaceutical ingredients in an inert
carrier or matrix in the solid state, prepared by a fusion
method [20]. They are produced by the rapid solidification
of the fused melt of the components. Thermodynamically,
this system is a physical mixture of the crystalline
components.
The aim of our work was to apply melt technology to
develop a pastille as lozenge solid dosage form, which has
fast dissolution rate of PCT (within 15 min). To find pas-
tille basis, the eutectic mixture of xylitol and mannitol was
investigated and the effect of PEG as softener material was
controlled on the eutectic formation and the recrystalliza-
tion of PCT. The thermal behaviour of the components and
the product was investigated by means of differential
scanning calorimetry (DSC), and the polymorph modifi-
cations were checked with X-ray powder diffractometry
(XRPD) and dispersive Raman spectroscopy (DRS). The
distribution of PCT in the pastille was analysed by using
transmission Raman spectroscopy (TRS). The hardness of
pastilles was determined with a Heberlein hardness tester,
and the in vitro dissolution of PCT was investigated.
Materials and methods
Materials
D-Xylitol ((2R,3R,4S)-pentane-1,2,3,4,5-pentol) was pur-
chased from Carl Roth GmbH & Co. KG (Karlsruhe,
Germany), and b-D-mannitol ((2R,3R,4R,5R)-hexane-
1,2,3,4,5,6-hexol) was from Sigma-Aldrich Chemie GmbH
(Mannheim, Germany). The monoclinic form of PCT (N-
(4-hydroxyphenyl)acetamide) was chosen as model mate-
rial for the experimental work; it was obtained from Sanofi
Aventis (Frankfurt am Main, Germany) and PEG 6000
from FERAK Laborat (Berlin, Germany).
Differential scanning calorimetry (DSC)
DSC measurements were taken to identify the eutectic
mixture of xylitol and mannitol, to investigate the role of
PEG and to study the recrystallization. The data were
recorded with a Netzsch DSC-204 instrument (Selb, Ger-
many) under a constant nitrogen flow of 30 mL min-1.
Solid xylitol–mannitol samples with xylitol contents of 10,
20, 30, 40, 50, 60, 70, 80 and 90 mass% were prepared in a
trituration mortar. 7 ± 0.2 mg samples were crimped in
aluminium pans with two holes and were examined in the
temperature interval 25–170 C at a heating rate of
2 C min-1. The melting temperatures for the phase dia-
gram were taken from the endset temperatures of the DSC
curves [6, 22]. Each measurement was baseline-corrected.
To estimate the eutectic concentration, parabolic curve
fitting was used.
Pastillization process
For pastillization, the one-drop pastillization device
developed by Kaiser Steel Belt Systems GmbH (Krefeld,
Germany) was used (Fig. 1).
Physical mixtures of xylitol and mannitol with PEG as
carrier were prepared and melted in a temperature-con-
trolled double-walled vessel at 110 C. PCT was dispersed
in the melted carrier. A crank shaft moved at constant rate
by an engine pressed the mixture in drop form through a
valve at the bottom of the vessel onto a 25 C thermostated
cooling plate, where it solidified into a flat-bottomed pas-
tille [6].
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X-ray powder diffraction (XRPD)
XRPD analysis of the pastille was performed with a Bruker
D8 Advance diffractometer (Bruker AXS GmbH, Karlruhe,
Germany) with Cu K kI radiation (k = 1.5406 A˚) and a
VA˚NTEC-1 detector. The samples were scanned at 40 kV
and 40 mA. The angular range was 3–40 2h, in steps of
0.1 s at a step size of 0.007. The sample was placed on a
quartz holder and measured at ambient temperature and
humidity. All manipulations, Ka 2-stripping, background
removal and smoothing of the area under the diffractogram
peaks were performed with DIFFRACPLUS EVA software.
Raman spectroscopy
PCT-containing pastilles were scanned first with a Cobalt
TRS 100 instrument (Cobalt Light Systems Ltd., Abing-
don, UK). The TRS technique is a fast, non-destructive
measurement with high sampling volume, which provides
data about the uniformity of the PCT content. The starting
PCT material and the PCT-containing pastilles were
scanned by TRS over the wavenumber range
1700–200 cm-1. Each reported spectrum is the average of
at least 3 scans with an exposure time of 1 s, a laser power
of 0.4 W and a laser spot size of 8 mm.
To investigate the difference between the different
forms of PCT and the pastilles, Raman spectra were
acquired with a Thermo Fisher DXR Dispersive Raman
instrument (Thermo Fisher Scientific. Inc., Waltham, MA,
USA) equipped with a CCD camera and a diode laser
operating at a wavelength of 780 nm. Raman measure-
ments were taken with a laser power of 12 mW at a slit
aperture size of 25 lm on a spot size of 2 lm. The spectra
of the individual PEG, mannitol and xylitol were collected
with an exposure time of 6 s, for a total of 48 scans in the
spectral range 1700–200 cm-1 with cosmic ray and fluo-
rescence corrections.
Technological parameters of the pastilles
Geometrical parameters and hardness
The diameter and the height of 20 pastilles were measured
with a screw micrometer (Starrett Co., Athol, MA, USA),
and their masses were measured with analytical scales.
The hardness of pastilles was determined with a
Heberlein hardness tester (Heberlein & Co. AG, Switzer-
land). Five pastilles were investigated to calculate the
average and standard deviation.
Drug content determination
A powdered pastille was taken in a 100-mL volumetric
flask, 15 mL of methanol was added, and the mixture was
shaken well to dissolve the powder. 85 mL of water was
then added to adjust the volume to 100 mL. 1 mL of
solution was next withdrawn and transferred to a 100-mL
volumetric flask. The volume was adjusted with methanol
to 100 mL. The dissolved PCT was investigated spec-
trophotometrically at 244 nm [23].
In vitro dissolution studies
The dissolution of PCT from pastilles and from compri-
mates of physical mixtures was determined according to
the European Pharmacopoeia (8th Edition) paddle method
(Pharmatest Heinburg, Germany). The paddle was rotating
in the dissolution vessel at 100 rpm. The dissolution
medium was 900.0 mL of purified water (pH 7.25 ± 0.1)
at 37 ± 0.5 C. At predetermined time intervals, 5 mL
samples were withdrawn and immediately filtered (cut-off
0.2 lm, Minisart SRP 25, Sartorius, Go¨ttingen, Germany),
and the amount of dissolved drug was determined spec-
trophotometrically at 244 nm.
Results and discussion
Phase diagram of sugar alcohols
In the development of a carrier system for melt technology,
the physico-chemical interactions of the components
should be examined in order to determine the optimum
composition for pastille-forming method.
Determination of the phase diagram of xylitol–mannitol
physical mixtures is necessary to find the eutectic melting
temperature and to understand the mechanism of crystal-
lization of the pastille (Fig. 2).
4
3
2
1
5
Fig. 1 Pastillization device (1—temperature-controlled plate, 2—
double-walled vessel, 3—crank shaft, 4—engine, 5—thermostat) [6]
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We collected the melting temperatures for the phase
diagram. The point of interception of the two curves
indicated the eutectic concentration at 90 mass% xylitol
and 10 mass% mannitol. The melting temperature of pure
xylitol was detected to be 97.6 C. The melting tempera-
ture of the eutectic composition dropped to 95.5 C. The
phase diagram suggests that phase separation between
xylitol and mannitol is theoretically possible. The melting
temperature of pure mannitol (169.5 C) can be decreased
by more than 70 C in the eutectic mixture.
We found that during the recrystallization of the pastille,
a phase separation occurs. A well-defined shell and core
structure can be differentiated; therefore, the phase sepa-
ration was investigated with DSC (Fig. 3).
The melting temperatures of the core and shell of the
pastille are different. The melting temperature of the shell
is 97.6 C, parallel with the melting temperature of starting
xylitol. The melting temperature of core structure is
95.5 C, which is parallel to the eutectic temperature. It
means the eutectic composition located in the core of the
pastille.
Because the eutectic mixture of xylitol and mannitol
results in rapid solidification, therefore it is necessary to
apply PEG, as softener material. According to the literature
data, it has no influence on the recrystallization of the
components (xylitol, mannitol and PCT) but promotes the
formation of pastille dosage form [5]. The ternary phase
diagram of the xylitol, mannitol and PEG was also inves-
tigated in certain cases. 100 mg solid xylitol–mannitol
samples in different ratios were prepared with constant
amount of PEG (7.81 %) to determine the ternary phase
diagram. The melting temperatures were analysed by DSC
at a heating rate of 2 C min-1. Parabolic curve fitting was
applied to investigate the effect of the polymer on the
eutectic concentration (Fig. 4). It turned out that, in the
presence of this quantity of PEG, the eutectic concentration
of xylitol and mannitol was at 80 mass% xylitol and
20 mass% mannitol.
Optimization of eutectic formula
Our target was to develop a pastille containing 40 mg PCT.
Since PEG was found to influence the eutectic concentra-
tion, a Box–Behnken experimental design was carried out
to optimize the formulation as concerns the carrier. Three
experimental factors (xylitol, mannitol and PEG) were
varied in the design, at 3 levels in 15 runs, so as to con-
struct the surface plot for the optimization process
(Table 1) according to the recrystallization time.
Recrystallization began on the shell of the pastille and
tends inwards to the core. If this process takes place too
quickly, the dissolved melt components with higher melt-
ing temperatures (PCT and mannitol) recrystallize first and
their crystals sink to the bottom of the pastille, resulting in
an inhomogeneous distribution. A composition was first
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Fig. 2 Phase diagram of the xylitol–mannitol system
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sought at which recrystallization was slow enough to pre-
serve the homogeneous distribution of the components.
The experimental results showed that each of the three
components exerted a significant effect on the recrystal-
lization. At a 95 % confidence level, the coefficients dif-
fered from zero and the P values were\0.05, the time of
recrystallization depending significantly on the fractions of
the components. The surface plot illustrates the recrystal-
lization times of the different component ratios (Fig. 5).
The surface plot depicts recrystallization times from 1 to
5 days. The maximum in the plot is observed at
61.25 mass% xylitol, 15.31 mass% mannitol, which cor-
responds to the eutectic composition. The composition also
included 7.81 mass% PEG, and the PCT content of the
pastille was 15.63 mass%. The calculations indicated that
the pastille mass should be *256 mg containing the 40 mg
of PCT.
Pastillization of the carrier
Pastillization took place on the surface of a thermostated
cooling plate at 25 C for 24 h. Because of the relatively
high viscosity of the melt, the molecular mobility was
decreased and crystallization was hindered in the core.
PEG does not prevent the recrystallization of the compo-
nents as poor crystallization inhibitor to form the pastille.
In order to initiate crystallization, pure xylitol crystals were
used as seeds [24].
After 24 h, a thin xylitol shell crystallized on the surface
of the pastille, which gradually thickened during the stor-
age until the whole of the pastille had solidified. After
5 days, the core was fully solid as shown previously by the
surface plot (Fig. 5), but after 3 days, the DSC analysis
demonstrated that the crystallization of the sample was still
taking place. Figure 6 presents DSC curves of samples
stored for various times.
The endotherms in the DSC curves indicate the melting
temperature of xylitol. The increasing area of the peaks
reflects the extent of crystallization. As the crystallization
progresses, the glass transition undergoes a depression.
Table 2 shows the DSC data of recrystallization.
Table 1 Variables and their levels in the Box–Behnken design
Levels
-1 0 1
Independent variables/factors Contents of components/mass%
Xylitol 48.13 61.25 75.94
Mannitol 6.88 15.31 25.31
PEG 0 7.81 15.63
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Fig. 5 Surface plot illustrating optimization of the xylitol–mannitol–
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Fig. 6 Recrystallization of the pastille carrier
Table 2 DSC data of recrystallization compared to physical mixture
Time of
measurement/h
Melting
temperature/C
Fusion enthalpy/
J g-1
24 88.59 12.47
48 89.36 104.81
72 90.50 123.16
120 95.50 168.57
Physical mixture 95.40 168.27
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Pastillization process with PCT
The aim of our work was to formulate a pastille containing
PCT and sugar alcohols. This has the advantage that pastil-
lization occurs in a single step. On the basis of the factorial
design, for pastillization 61.25 mass% xylitol, 15.31 mass%
mannitol, 7.81 mass% PEG and 15.63 mass% PCT were
used, as indicated in Fig. 5. This gave the best pastille shape
without visible pores and with a homogeneous shell texture.
The PEG content resulted in an appropriate crystallization
time and decreased the melting temperature of the mixture
through the formation of a solid dispersion [25]. DSC curves
of the components are presented in Fig. 7. The DSC curves
show that the melting temperature of mannitol is not seen at
the eutectic composition (compare A and E). The melting
temperature of xylitol can still be observed at the eutectic
compositions, but much less strongly (compare B and E).
The endotherm of PEG is greatly reduced in the eutectic
mixture (compare C and E).
After storage of 5 days, the pastille and the physical
mixture were investigated by DSC and compared. The
DSC curves of the recrystallized pastille and initial com-
ponents are shown in Fig. 8.
The DSC curves demonstrate that the high melting
temperature of PCT (A) is not seen in the DSC curves of
the physical mixture and the pastille (B and C), as a result
of the PCT partly dissolving in the melt of the eutectic.
X-ray powder diffraction (XRPD)
Because of the fusion of PCT in the eutectic, the possibility
of polymorphic transition of the API during the recrystal-
lization must be considered. PCT has three crystal modi-
fications: a monoclinic form I, which has poor direct
compressibility, an orthorhombic form II, and an unsta-
ble phase (form III), which can be stabilized only under
certain conditions (for example, between a microscopy
slide and a cover glass) [26]. XRPD measurements were
taken to identify the polymorphic form of the PCT in the
product. Comparison of the diffractogram of the starting
PCT with the diffractograms of the various crystal modi-
fications available from the Cambridge Crystallography
Data Centre (CCDC ID: AI631510) revealed that the
starting PCT was in monoclinic form I (Fig. 9).
The core structure of the pastille was investigated after
5 days by means of XRPD; the diffractograms are pre-
sented in Fig. 10.
The characteristic peaks of the components can be
traced in the diffractogram of the pastille core. The char-
acteristic peaks of the PCT in the core at 13.924 and
23.557 2h indicate the presence of the monoclinic form I.
Since the peaks of orthorhombic form II are overlapped, we
had to use Raman spectroscopy to prove its presence.
Raman spectroscopy
Because of the slow solidification, the distribution of the
PCT in the pastilles was first investigated by TRS. The
transmission Raman spectra of pure PCT (a) and the PCT-
containing pastille shell (b) and core (c) are shown in
Fig. 11. The spectra in b and c are basically identical, the
almost negligible differences involving new peaks due to
the non-PCT ingredients. The pastille spectra indicated that
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Fig. 7 DSC curves of the components, the eutectic and the physical
mixture: a mannitol, b xylitol, c PEG, d physical mixture, e eutectic
mixture of xylitol and mannitol with PEG
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Fig. 8 DSC curves of PCT and xylitol–mannitol–PEG–PCT physical
mixture and pastille: a PCT, b the physical mixture of components,
c pastille
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there was no change in the crystal modification of the
material in the sample tray during the measurement, the
main characteristic Raman bands of PCT in the intervals of
1660–1540, 1400–1160, 870–770 and 660–560 cm-1. The
identity of spectra b and c confirmed the uniform distri-
bution of PCT throughout the pastilles.
To identify the polymorphic forms of the PCT after the
recrystallization, DRS spectra were acquired with a DXR
instrument. The DXR Raman spectra of all the PCT forms
produced in various modes of the heating–cooling process
were identical and were those of the metastable orthorhombic
polymorph of PCT form II (not shown). The Raman spectrum
of PCT displays strong bands at 1648, 1610, 1561, 1323,
1236, 857, 796, 650 and 390 cm-1, assigned to –NHCOCH3
stretching, C–C Ar stretching, C–N stretching/in-plane N–H
bending, C–N stretching, phenyl-N and Ar C–C stretching,
out-of-plane C–C skeletal deformation, C–N–C stretching and
Ar=C–H out-of-plane deformation, respectively (Fig. 11a).
Table 3 lists the principal Raman bands of PCT, and selected
Raman bands of mannitol, PEG and xylitol are presented in
Fig. 12. Though most of the main and characteristic Raman
bands of the ingredients and PCT overlap, differentiation of
the PCT is of primary importance. The highlighted Raman
bands at 1660–1540, 1168, 710 and 390 cm-1 were used to
identify the PCT in the pastilles.
Figure 13 presents DXR spectra of the starting PCT, form
II, and the PCT in the pastille shell and the core. The most
marked differences between the two polymorphic PCT forms
are to be seen in the highlighted regions, i.e. the intense
Raman double peak at 1617–1610 cm-1 was split into two
peaks at 1623 and 1608 cm-1 and one new peak appeared at
1575 cm-1, in parallel with a decrease in intensity of the peak
at 1560 cm-1. The PCT form II spectrum exhibits the char-
acteristic peaks of the starting PCT, but shifted to higher
wavenumber as: 1561 ? 1575, 1371 ? 1374,
1323 ? 1326, 857 ? 860, 833 ? 837, 503 ? 508 and
328 ? 330 cm-1. This indicates that the corresponding
chemical bonds are in a higher energy state. Table 3 lists the
principal Raman bands of PCT form II, the metastable phys-
ical state, having a higher energy state than that of the starting
PCT which is consistent with the reported data. The excep-
tions (1256 ? 1244, 1236 ? 1219 and 464 ? 453 cm-1)
are attributed to the symmetrical CH3 deformation, the phe-
nyl-N and aromatic C–C stretching and the skeletal bending
of PCT. The presence of PCT in the pastilles was not asso-
ciated with the formation of the metastable PCT, form II.
These data confirm the PCT is in the thermodynamically
stable monoclinic form. It should be mentioned that the core
of the pastille (d) contains more xylitol than the outer shell
(c), e.g. the characteristic weak or moderate Raman bands of
xylitol are not present at 1461, 1092, 1071, 1059 and
426 cm-1 in the spectrum of the pastille shell. The higher
xylitol concentration in the pastille core was confirmed by the
presence of the characteristic Raman peaks of xylitol at 1461,
1003, 426 and 355 cm-1 (Fig. 13d), which were absent from
the Raman spectrum of the pastille shell (Fig. 13c).
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Fig. 9 Diffractograms of the polymorphic forms of PCT and the
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Fig. 10 Diffractograms of the pastille and the components
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Technological parameters of pastille
Geometrical parameters and hardness
The diameter and the height of 20 pastilles were measured
with a screw micrometer and their mass with analytical
scales. The average diameter of the pastilles was
10.60 ± 0.31 mm, the height was 3.11 ± 0.23 mm, and
the mass was 256.68 ± 1.99 mg. Figure 14 illustrates the
top view (A) and the largest vertical cross section (B) of the
drop-melted pastille.
The breaking hardness of 5 pastilles was measured. The
average hardness of the pastilles was 125 ± 5 N, which is
corresponded to the requirements of dosage form.
1600 1400 1200 1000 800 600 400
Wavenumber/cm–1
1660–1540 1400–1160 870–770
660–560
(a)
(b)
(c)
Fig. 11 Transmission Raman
spectra of the starting PCT (a),
the shell of the PCT-containing
pastille (b) and the core of the
PCT-containing pastille (c)
Table 3 Observed Raman peaks and their assignments for the starting PCT, form II of PCT and the PCT-containing pastille/shell and core
PCT PCT form II Pastille shell Pastille base Assignment
464w 453w 465w 464w Skeletal bending
503m 508w 505w 505w Ar ring deformation
650s 650s 652m 652m Ar=C–H out-of-plane deformation
710m 709w 711w 711w Out-of-plane CN–H and phenyl deformation
796s 798m 798m 798m Phenyl-N bending and out-of-plane p-substituted
Ar ring deformation
857vs 860s 858s 857s Out-of-plane C–C skeletal deformation
968w 966w 969w 970w C–C stretching
1104w 1106w 1105w 1109w CH3 rocking
1236s 1219m 1237s 1238m Phenyl-N and Ar C–C stretching
1256w 1244w 1257w 1257w Symmetrical CH3 deformation
1323s 1326vs 1324s 1324s C–N stretching
1515w 1510w 1515w 1517w Secondary amine deformation
1561m 1560w-sh 1561m 1562w C–N stretching and in-plane N–H bending
– 1575m – – Amide N–H deformation
1610s 1608s 1610s 1611s C–C Ar stretching
1617vw-sh 1623s 1619sh 1619sh Asymmetrical C=C Ar stretching, C–N stretching
1648s 1648m 1648s 1648m –NHCOCH3 stretching
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Drug content determination
Before the in vitro dissolution studies, the drug content of
the pastilles was determined. Three different batches were
investigated. The calculated and spectrophotometrically
measured PCT contents of the pastilles were 40.19 mg and
40.12 ± 0.31 mg, respectively.
In vitro dissolution studies
In three parallel measurements, the dissolution of the
pastilles was compared to that of the pure PCT crystals. In
both case, the PCT was practically fully dissolved in the
medium after 15 min (Fig. 15). Because of the relatively
low porosity and surface area of the drop-melted pastille,
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they dissolved more slowly than the starting PCT crystals
in the media (and would behave similarly in the mouth).
Discussion
In this study, the xylitol–mannitol–PEG eutectic mixture
was successfully applied to produce a PCT-containing
pastille. New finding in this work is the development of a
crystalline carrier/basis for pastilles which consist of two
well-recrystallized sugar alcohols as poor glass formers and
the PEG as poor crystallization inhibitor. This carrier
system is suitable to use a melt technology to formulate of
a pastilles containing crystalline PCT. These are important
viewpoints to the stability of the final product. The melt
technology is an innovative technology because there is no
need for the use of extra organic solvents, it is a dust-free
process, and the formation of the product is in one process
step.
Determining the phase diagrams, we obtained the
eutectic mixture of xylitol and mannitol confirmed by DSC
(90 mass% xylitol and 10 mass% mannitol with the melt-
ing temperature of 95.5 C), which coincides with data of
Detherm database [21]. Investigating the pastille shell and
core structure, we found a phase separation with the
eutectic composition of xylitol and mannitol located in the
core (Fig. 3). The phase separation in the pastille form was
first described by Ulrich et al. [6]. As a component of the
carrier, PEG served as a softener agent and did not inhibit
the recrystallization of the components (xylitol, mannitol
and PCT), but the solidification would be slower which
promoted the pastille forming.
The pastillization was optimized both statistically with a
Box–Behnken design and experimentally via the phase
diagrams. The factorial design led to a carrier containing a
eutectic mixture of xylitol (61.25 %) and mannitol
(15.31 %) with 7.81 % of PEG. The components of the
pastilles containing 15.63 % PCT recrystallized completely
after 5 days. The relatively appropriate distribution of PCT
was confirmed by TRS, which revealed the homogeneous
distribution of the PCT both in the shell and in the core of
the pastille. The DSC curves indicated that the PCT dis-
solved in the melted mixture of sugar alcohols and PEG,
and the polymorphism of PCT during the recrystallization
was therefore investigated by DSC, which demonstrated
the occurrence of recrystallization, but did not allow
identification of the polymorphs. XRPD of the pastilles
revealed only the monoclinic form I of PCT in the product.
However, DRS showed that the monoclinic and
orthorhombic forms of PCT can be distinguished from each
other and the other components. Mainly, the thermody-
namically stable form of PCT was observed in the pastilles,
but its distribution depended strongly on the structure
formed during the pastille formation and on process
parameters such as the cooling rate and time. In this
respect, the XRPD and Raman investigations supplement
thermal analysis in the determination of the polymorphs
present. The pastilles hardness proved to be relatively hard
(125 ± 5 N). Their PCT content, 40.12 ± 0.31 mg, satis-
fied the requirements of the European Pharmacopoeia (Ph.
Eur. 8.), and in vitro dissolution studies showed that 100 %
of the PCT dissolved in from the drop-melted pastille
\15 min. It may be concluded that the pastillization via
melt technology is suitable for the development of PCT-
containing pastilles as a solid dosage form.
This work allows the application of developed carrier
system and the melt technology to have a PCT-containing
pastille as new lozenge dosage form for children therapy.
(a) (b) Pastille shell Pastille core
Fig. 14 The top view (a) and
the largest vertical cross section
(b) of the drop-melted pastille
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Fig. 15 Dissolution profiles of pure PCT and drop-melted pastille
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The focus of this researchwas to apply the in situ coating technology for producing paracetamol- (PCT-) contain-
ing pastilles for paediatric use from a eutectic of two sugar alcohols (sorbitol, xylitol) in one step. This type of
melt-technology is more cost-efﬁcient and simpler than other conventional tableting technologies, whereby
the formation of the pastilles and their coating occur upon the same fabrication step. We managed to produce
pastilles having a softer core and a harder, resistant shell in one cooling step. Adding polyethylene glycol
(PEG) 2000 or 6000 to the PCT-containing eutectic, the dissolution rate of PCT could be considerably increased,
especially when using PEG 2000, reaching equal dissolution characteristics both under mouth- and gastric-spe-
ciﬁc conditions. Distributions of the components within the pastilles have been determined by X-ray scattering
and Raman spectroscopy. Physico-chemical parameters of the xylitol-sorbitol eutectic and their changes upon
adding PCT and PEGs have been determined, and it has been revealed that xylitol and sorbitol form a new entity
with a distinguished crystal structure. The signiﬁcant changes in viscosity were explained and the interaction in
the eutectic mixture was investigated using Fourier transform infrared spectroscopy (FT-IR). The uniformity of
the physical parameters of the pastilles (including size, weight and drug content) also demonstrates the feasibil-
ity of using the cost-efﬁcient and simple one-step eutectic-cooling technology for manufacturing pastilles.
© 2016 Elsevier B.V. All rights reserved.
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1. Introduction
In situ coating is a novel approach in melt technology developed by
Ulrich et al. (Wendt et al., 2014; Ulrich et al., 2015; Abouzeid et al.,
2014), in which the formation of the pastille and its coating occur in
the same step. Upon using a eutectic mixture of two compounds (e.g.
sugars or sugar alcohols), phase separation can take place and either
of the componentsmay form a coating. As phase separation is a thermal
process, recrystallization of the amorphized components can be investi-
gated (Patterson et al., 2005; Mah et al., 2015; Löbmann et al., 2013).
Drop-melting method is a suitable technique for pastille formation,
where solidiﬁcation takes place at the surface of the pastilles, corre-
sponding to the recrystallization of the components. Viscosity is a criti-
cal parameter of this technology: it inﬂuences drop size, whereas a
relatively high viscosity decreases molecular mobility, thereby hinder-
ing the recrystallization process and surface solidiﬁcation (i.e. formation
of the “coating” or “shell”). In case of high viscosity, seed crystals or ul-
trasonic agitation can be used to initiate nucleation (Wendt et al., 2014).
Sugar alcohols such as xylitol, mannitol and sorbitol are often used
as sweeteners in orally disintegrating drug formulations (Ciper and
Bodmeier, 2005; Slavkova and Breitkreutz, 2015) or in chewing gums
because of their low glycaemic index and anticariogenicity (Burt,
2006; Aslani and Jalilian, 2013; Kartal et al., 2007). They can also be
used as plasticizers in ﬁlms (Talja et al., 2007; Zhang and Han, 2006;
Krogars et al., 2002; Sharma et al., 2016) andmay substitute for glycerol
in preparing soft gelatine capsules (Moreton and Armstrong, 1998).
Sugars and sugar alcohols form eutecticmixtureswith each other in cer-
tain ratios, resulting in a systemwith a lowermelting temperature than
that of either of the components (Sugar alcohol eutectic and process for
producing the same EP 1842436 A1, 2015). Literature examples of eutec-
tic-forming mixtures include xylitol–isomalt (Wendt et al., 2014) and
xylitol–sorbitol (Diarce et al., 2015).
In the USA, a buccal pharmaceutical preparation, Meltaways®
(Tylenol) containing 80mg of paracetamol (PCT) is available as a chew-
able tablet in paediatric therapywith the aimof easy administration and
fast release. Although it is most often used for a localized painkiller ef-
fect in the mouth, it can also be used for systemic therapy provided
that the drug is in contact with the oral cavity for an extended period
or is swallowed. By means of buccal absorption, several disadvantages
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of oral administration can be avoided, including the hepatic ﬁrst-pass
metabolism or enzymatic degradation within the gastrointestinal
tract, which prevent the oral administration of certain classes of drugs,
particularly of proteins and peptides (Sholaei, 1998). Additionally, by
buccal administration a lower amount of drug is needed to achieve
the desired therapeutic effect.
In our previous studies we applied melt technology for the formula-
tion of pastilles containing PCT (15.63%) as a model active agent, plus
xylitol (61.25%), mannitol (15.31%) and polyethylene glycol 6000
(PEG 6000) (7.81%) as carriers (Katona et al., 2016). It was found that
the components of the pastilles underwent recrystallization at different
rates within the ﬁrst 5 days after production, and phase separation,
resulting in the appearance of a “shell” on the surface of the pastilles
was detected. As an extension of our previous research, the goal of our
current studywas to investigate the recrystallization of the components
within the pastille, focusing on the upcoming polymorphs and the dis-
tribution of PCT within the product.
The focus of our current research was to apply an in situ coating
technology to produce PCT-containing pastilles, using PEG 2000, PEG
6000 and two sugar alcohols (sorbitol and xylitol) of similar melting
temperatures, as well-known taste-masking agents for paediatric ther-
apy. Cooling of a eutectic mixture can produce either an “overcooled”
liquid core or a recrystallized outer shell.We aimed to discover how sor-
bitol as a “good glass former” material inﬂuences the glass transition
value (Tg) of the eutectic. All physical parameters of possible relevance
in terms ofmedical application of such pastilleswere characterized. Fur-
ther aimsof our studywere to investigate thewetting effect of PEG 2000
and 6000 affecting the extent of dissolution of PCT compared to the sim-
ple eutectic, as well as their softening and viscosity-enhancing effects
affecting the formation of the pastille shape. Solidiﬁcation was studied
both by X-ray powder diffraction (XRPD) and by dispersive Raman
spectroscopy (DRS), whereas the molecular interactions between the
components within the pastilles were investigated by Furier transform
infrared spectroscopy (FT-IR).
2. Materials and methods
2.1. Materials
D-Xylitol ((2R,3R,4S)-pentane-1,2,3,4,5-pentol), polyethylene glycol
2000 (PEG 2000) and polyethylene glycol 6000 (PEG 6000) were pur-
chased from Sigma-Aldrich Chemie GmbH (Mannheim, Germany). D-
Sorbitol ((2S,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol) was purchased from
Molar Chemicals Ltd. (Halásztelek, Hungary). The monoclinic form of
PCT (N-(4-hydroxyphenyl)acetamide) was chosen as a model active
agent for the experimental work; and it was obtained from Sanoﬁ
Aventis (Frankfurt am Main, Germany).
2.2. Investigations of the xylitol–sorbitol eutectic composition
2.2.1. Differential scanning calorimetry (DSC)
DSC measurements were carried out to characterize the eutectic
mixture of xylitol and sorbitol, and to investigate the role of PEG. DSC
data were recorded with a Mettler-Toledo 821e DSC instrument
(Mettler-ToledoGmbH, Greifensee, Switzerland). 100mg of xylitol–sor-
bitol solid dispersions with xylitol contents of 10, 30, 40, 50, 60, 70, and
90 wt.% were prepared in a trituration mortar. Samples of 5 ± 0.2 mg
were crimped in 3-hole aluminium pans and were examined in the
temperature interval of 25–110 °C at a heating rate of 2 °C min−1
under a constant argon ﬂow of 150 ml min−1. Next the samples were
cooled to−40 °C and then reheated to 110 °C at a heating rate of 2 °
C min−1 under a constant argon ﬂow of 150 ml min−1 and a nitrogen
ﬂow of 50 ml min−1 to study glass transition (Tg). Data were analyzed
by a STARe software. Eachmeasurementwas normalised to sample size.
2.2.2. Viscosity measurements
Rheological measurements were carried out at 110 °C using a
Physica MCR101 rheometer (Anton Paar GmbH, Graz, Austria). A paral-
lel-plate measuring device was used with a diameter of 25 mm and
0.20 mm gap height. Shear rate was increased from 0.1 to 100 s−1 in a
controlled rate mode. Shearing time was 300 s.
2.2.3. Contact angle measurements
The melted compositions were cast on a slide, where they solidiﬁed
with a ﬂat surface on which contact angle measurements were carried
out. The contact angle (θ) was determined by means of the sessile
drop technique, using an OCA 20 Optical Contact Angle Measuring
System (Dataphysics, Filderstadt, Germany) and the method of Wu.
The liquid mediums used for our contact angle measurements
included bidistilled water (interfacial tension of polar component
(γp) = 50.2 mN/m, interfacial tension of disperse component (γd) =
22.6 mN/m) and diiodomethane (γp=1.8 mN/m, γd=49mN/m). Po-
larity percentagewas calculated from the interfacial tension of the polar
component (γp) and the surface free energy (γ) values as follows:
Polarity %ð Þ ¼ γ
p
γ
 
 100 ð1Þ
2.3. Pastillization process
Eutectic mixtures of xylitol and sorbitol with PEGs as carrier addi-
tives were prepared and melted in a heated pipette at 110 °C. PCT was
dispersed in the melted carrier. The melted solid dispersion was
dropped onto a 25 °C thermostated cooling plate, where it solidiﬁed to
form ﬂat-bottomed pastilles (Fig. 1) (Bülau andUlrich, 1997). Fourmix-
tures were studied, including (1) xylitol/sorbitol 50–50wt.% (referred to
as eutectic) without PCT, (2) xylitol-sorbitol with PCT (14.29%) (referred
to as EuPCT), (3) xylitol–sorbitol–PCTwith PEG 2000 (7.81%) (referred to
as EuPCT 2000) and (4) xylitol-sorbitol-PCT with PEG 6000 (7.81%) (re-
ferred to as EuPCT 6000).
2.4. Investigation of pastilles of different compositions
2.4.1. X-ray powder diffraction
XRPD analysis was performed using a Bruker D8 Advance diffrac-
tometer (Bruker AXS GmbH, Karlsruhe, Germany) with Cu K λI radia-
tion (λ= 1.5406 Å) and a VÅNTEC-1 detector. Samples were scanned
at 40 kV and 40 mA. The angular range was 3° to 40° 2θ, at a step time
of 0.1 s and a step size of 0.007°. The sample was placed on a quartz
holder, andmeasured at ambient temperature and ambient relative hu-
midity. Allmanipulations, includingKα 2-stripping, background remov-
al and smoothing of the area under the peaks of the diffractogramswere
performed using the DIFFRACTPLUS EVA software.
2.4.2. Raman spectroscopy
To investigate the difference between the shell and the core struc-
tures of the pastilles, Raman spectra were acquired by a Thermo Fisher
DXR Dispersive Raman instrument (Thermo Fisher Scientiﬁc. Inc., Wal-
tham, MA, USA) equipped with a CCD camera and a diode laser operat-
ing at a wavelength of 780 nm. Raman measurements were carried out
with a laser power of 12mWat a slit size of 25 μmon a spot size of 2 μm.
Spectra of the individual PEGs, sorbitol and xylitol were collected with
an exposure time of 6 s, for a total of 48 scans in the spectral range of
1700–200 cm−1 with cosmic ray and ﬂuorescence corrections.
2.4.3. Furier transform infrared spectroscopy (FT-IR)
Kalium bromide pastilles were prepared by hydraulic press contain-
ing either the eutectic or a physical mixture of the components, and
their spectra were compared to each other. FT-IR spectra were recorded
by an Avatar 330 FT-IR spectrometer (Thermo Nicolet, USA), equipped
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with a DTGS (deuterated triglycyl sulfate) detector, in the range of
4000–400 cm−1. The spectral resolution was 4 cm−1, and 64 scans
were collected to provide a good signal-to-noise ratio. All spectral ma-
nipulations were performed using a GRAMS/AI Ver. 7 (Thermo Galactic,
USA) software.
2.4.4. Geometrical parameters and hardness
The diameter and the height of 20 pastilles were measured with a
screw micrometer (Starrett Co., Athol, MA, USA) and their masses
were measured using an analytical scale (Mettler Toledo AX205 Delta
Range analytical scale, Mettler Toledo GmbH, Greifensee, Switzerland).
Hardness of the pastilles was analyzed by a Heberlein hardness tes-
ter (Heberlein & Co. AG, Switzerland). Five randomly selected pastilles
were investigated to calculate the average and the standard deviation.
2.4.5. Drug content analysis
A powdered pastille plus 15 ml of methanol was shaken in a 100 ml
volumetric ﬂask until the powder got dissolved. Then 85 ml of water
was added to adjust the volume to 100 ml. Next a 1 ml alliquot was
transferred to a 100 ml volumetric ﬂask and was mixed with metha-
nol/water 15:85 to 100 ml. The dissolved amount of PCT was analyzed
spectrophotometrically at 244 nm (PerkinElmer, Lambda 20 spectro-
photometer, Dreieich, Germany) (Behera et al., 2012).
2.4.6. In vitro dissolution studies
The dissolution proﬁle of PCT from pastilles of different composi-
tions was determined according to the USP-2 paddle method
(Pharmatest, Heinburg, Germany). The rotating velocity of the paddle
within the dissolution vessel was 75 rpm. The dissolution studies
were carried out in 100.0 ml of phosphate buffer solution at pH 6.8 ±
0.1 characteristic of the oral cavity and at normal body temperature of
37 ± 0.5 °C, as well as in 900.0 ml of 0.1 N HCl at a gastric pH of
1.2 ± 0.1 at 37 ± 0.5 °C (Mashru et al., 2005; Gahel et al., 2009). At
predetermined time intervals, 5ml samples were taken and ﬁltered im-
mediately (using aMinisart SRP 25, Sartorius, Göttingen, Germany; pore
size: 0.2 μm,), and the amount of dissolved drug was determined spec-
trophotometrically at 244 nm (PerkinElmer, Lambda 20 spectropho-
tometer, Dreieich, Germany).
3. Results and discussion
3.1. Studies of the eutectic xylitol–sorbitol composition
3.1.1. DSC studies
100mg solid xylitol–sorbitol dispersions of different ratioswere pre-
pared. DSC curves of pure sorbitol, pure xylitol and of the investigated
dispersions are presented in Fig. 2. As it is apparent, sorbitol is
characterized by two endothermic peaks, showing that it consists of
two polymorphic forms. The peak at 85.4 °C indicates the melting
point of the Δ form, whereas the peak at 98.2 °C indicates the melting
point of the γ form. The Δ form of sorbitol was used by constructing
the phase diagram. Pure xylitol has a characteristic melting point at
93.4 °C.
The DSC curves of the dispersions indicate that sorbitol and xylitol
form a binary eutectic system, as supported by literature data (Diarce
et al., 2015). A binary phase diagram was constructed based of the
DSC curves to ﬁnd the eutectic concentration of xylitol and sorbitol
(Fig. 3).
The point of intersection of the two curves on the binary phase dia-
gram indicates the eutectic concentration at 50 wt.% sorbitol and
50 wt.% xylitol. The melting point of the eutectic composition proved
to be 76.9 °C. The phase diagram suggests that phase separation be-
tween sorbitol and xylitol is theoretically possible.
Eutectic melting enthalpy ΔH (J/g) values for the different xylitol–
sorbitol dispersions, as determined by the integration of the eutectic
peak area, were plotted versus the mass ratio of xylitol in order to con-
struct the Tamman's triangle showing the eutectic ratio of sugar alco-
hols at the maximal melting enthalpy value (Fig. 4) (Rycerz, 2013).
The enthalpy of the eutectic composition is maximal (ΔH=101.1 J/
g) and converges to zero for compositions corresponding to the pure
components. These data conﬁrm that xylitol and sorbitol form a eutectic
mixture in a 50–50 wt.% ratio.
Fig. 1. Pastillation process and solidiﬁcation of the pastilles.
Fig. 2. DSC curves of pure sorbitol (SORB), pure xylitol (XYL) and solid dispersions of
various ratios of xylitol–sorbitol (XYL/SORB).
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After identifying the eutectic composition, PEG 2000 (7.81%) and
6000 (7.81%) were added to the eutectic dispersions. Melting points
(Tm) and Tg of the different eutectic xylitol–sorbitol+PEG compositions
were studied byDSC. Theﬁrst heating curve shows themeltingpoints of
each component and every composition,whereas the secondheating al-
lows the detection of glass transitions (Table 1.). It has been revealed
that during heating both PEGs melt separately from the compositions.
We suppose that the lower Tm and Tg values of the eutectic + PEG
6000 mixture results from the interaction of PEG 6000 with one of the
eutectic components (Table 1).
3.1.2. Viscosity measurements
Viscosity of the melted dispersions is a critical parameter for drop
formation. High viscosity decreases molecular mobility, and therefore
hinders recrystallization. For our viscositymeasurements, all the disper-
sions were melted on a heated magnetic stirrer, then the melt was
thermostated on the plate of the viscosity measuring device. Measure-
ments were carried out at a constant temperature of 110 °C. All mea-
surements were performed in triplicate and the average values are
shown in Table 2.
Viscosity values of all samples were similar. Viscosity of the sample
containing PEG 2000was slightly higher than that of the one containing
PEG 6000. This phenomenon was unexpected because the viscosity of
pure PEGs is known to increase with their molecular weight. To clarify
this behaviour of the samples, viscosity measurements were expanded
using other compositions containing PEGs in different ratios (5%, 10%,
15%, 20%, 60%, 100%). Fig. 5 shows the viscosity of the different
compositions.
Fig. 5 shows that the viscosity of the eutectic without PEG 6000 and
that of pure PEG 6000 is almost the same, suggesting that no signiﬁcant
viscosity changes for the eutectic plus PEG 6000 composition can been
expected. However, our results showed that the viscosity curve has a
minimum at 10% PEG 6000 concentration. On the contrary, PEG 2000
is characterized by a signiﬁcantly lower viscosity than the eutectic with-
out PEG 2000, thus increasing the concentration of PEG 2000 in the
composition is associated with a drastic decrease of the viscosity of
the sample (Fig. 5). This viscosity-changing effect of PEGs strongly de-
pends on their molecular weight. Therefore, using a low (b20%) PEG
concentration, samples containing either PEG 2000 or 6000 are charac-
terized by similar viscosity values.
3.1.3. Contact angle measurements
Wettability of the pastilles has a signiﬁcant inﬂuence on the dissolu-
tion rate and the drug release characteristics of oral drug delivery. Wet-
tability is characterized by the contact angle of the liquid (water). A
smaller contact angle indicates a betterwettability of the pastille. To for-
mulate a pastillewith appropriate dissolving characteristics, awell-wet-
ting surface is fundamental. The polarity percentage can be calculated
from the interfacial tension of the polar component (γp) and the surface
free energy (γ) as follows: (γp/γ) ∗ 100 (Table 3).
The results show that PEGs increase the surface free energies and po-
larities of the compositions containing no PCT. Data for the PCT-contain-
ing samples show that PCT has no effect on the γ value, indicating that
PCT dissolves in the melt of the eutectic and recrystallizes during the
solidiﬁcation. For those compositions containing both PCT and PEG,
the PEG component (especially PEG 2000) decreases γ and increases
polarity, which promotes the wetting of the pastille, and thus its
dissolution.
Fig. 3. Binary phase diagram of the xylitol–sorbitol system by plotting the melting points
of xylitol–sorbitol compositions versus their different weight ratios.
Fig. 4. Construction of the Tamman's triangle by plotting the xylitol–sorbitol eutectic
melting enthalpies ΔH at 76.9 °C versus their different weight ratios.
Table 1
Melting points (Tm) and glass transitions (Tg) of the xylitol–sorbitol–PEG compositions
and the pure components studied.
First heating Second heating
Tm (°C) TmPEG (°C) Tg (°C) Tm (°C) Tg (°C)
Sorbitol 98.2 – – – –1.6
Xylitol 93.4 – – – –19.5
Eutectic 76.9 – – – –10.9
Eutectic + PEG 2000 77.6 51.8 – 51.8 –11.0
Eutectic + PEG 6000 72.4 60.0 – 60.1 –14.3
Table 2
Viscosity data of the compositions to be pastilled (n = 3).
Composition Viscosity (mPas)
Eutectic 368 ± 3
Eutectic + PEG 2000 (7.81%) 370 ± 20
Eutectic + PEG 6000 (7.81%) 359 ± 13
Fig. 5. Viscosity of eutectic xylitol–sorbitol + PEG compositions containing different
concentrations of PEGs.
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3.2. Pastillization process
Pastillization took place on the surface of a thermostated cooling
plate at 25 °C for 24 h. During this process the relatively high viscosity
of the melt decreased molecular mobility and crystallization was hin-
dered in the core. PEG 2000 and 6000, applied as softeners to form ap-
propriate pastilles, did not prevent the recrystallization of the
components. Crystallization was initiated by pure xylitol crystals as
seeds (Talja and Roos, 2001).
3.3. Studies of the pastilles of different compositions
3.3.1. X-ray powder diffraction
XRPD measurements were carried out to analyze the shell and the
core structures of the pastilles. The diffractograms of the pure compo-
nents (Fig. 6A) were compared to that of the pastilles of different com-
positions (Fig. 6B).
The EuPCT shell contains PCT and xylitol, thus the characteristic peaks
of sorbitol at 10.055° and 10.595° 2θ could not be detected. The
diffractogramof the EuPCT core showsamorphous signs, but also contains
PCT crystals. These results suggest a homogenous distribution of PCT
within the pastille. The EuPCT 2000 shell and EuPCT 6000 shell contain
not only PCT and xylitol, but also the characteristic peaks of sorbitol are
detected. The EuPCT 2000 core contains PCT crystals, plus some
amorphous signs are detected. The diffractogram of the EuPCT 6000
core shows that the core structure is partly amorphous and contains sor-
bitol and PCT crystals. Since some characteristic peaks of the components
overlap,we needed to use Raman spectroscopy to locate the components.
3.3.2. Analysis of Raman spectra of the pastilles
Fingerprint regions (900–1700 cm−1) of Raman spectra of
the pastille components and spectra collected at different locations/
compositions of the pastilles were used for the analysis. To make
these comparable, all spectra were normalised to unit integral (i.e.
each data point of the spectrum was divided by the average intensity
of the spectrum and thenmultiplied with the number of the data points
in the spectrum). This approach assumes that the probabilities of the
Raman scattering, and the scattering/collecting conditions of the
Raman spectrum are the same for each component. Considering that
none of the components were absorbing around the Raman excitation
wavelength (780 nm), this seems to be a rather fair approximation.
Fig. 7A shows the Raman spectra of the pastille components. Raman
spectra of the pastilles recorded at different locations and in the pres-
ence/absence of different PEG molecules are shown in Fig. 7B. These
spectra were ﬁtted with the linear combination of the component spec-
tra, and the residuals remaining after ﬁtting are shown in Fig. 7C. Note
that in agreement with the composition of the pastilles, either PEG
2000 or PEG 6000 may be used in the ﬁts.
Certain regions of the residual spectra show large deviations from
zero both in the positive and the negative directions, indicating that
the combination of the components form a new quality within the pas-
tilles. This corresponds to molecular interactionswhich affect the vibra-
tional coordinates of the components, and might either be chemical
interactions, or just strong associations affecting the molecules.
In Fig. 7C two vertical lines indicate the region of largest turbulence
in the residual spectra. In this regionmainly xylitol, but also sorbitol and
PEG have complex bands (see Fig. 7A). We suppose an interaction for
Table 3
Contact angles, surface free energies and polarities of the different eutectic compositions studied.
Composition θwater (°) θdiiodomethane (°) γd (mN/m) γp (mN/m) γ (mN/m) Polarity (%)
Eutectic 28.1 ± 3.6 20.5 ± 2.9 42.96 31.74 74.70 42.49
Eutectic + PEG 2000 17.0 ± 1.47 29.7 ± 1.62 39.98 36.60 76.58 47.79
Eutectic + PEG 6000 21.6 ± 3.63 19.5 ± 2.72 43.22 34.03 77.25 44.05
EuPCT 26.7 ± 4.71 22.7 ± 1.84 42.33 32.49 74.82 43.24
EuPCT 2000 34.0 ± 1.82 47.9 ± 2.91 32.41 33.17 65.58 50.58
EuPCT 6000 30.1 ± 3.40 35.9 ± 1.45 37.62 32.77 70.39 46.55
Fig. 6. (A) Diffractograms of the pure components, compared to (B) the shell and the core structures of pastilles containing EuPCT plus different PEGs.
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xylitol and sorbitol, as these are very similar molecules. In addition, our
former studies (Katona et al., 2016) on similar pastilles containing no
sorbitol revealed no such anomaly in the residuals (see the insert in
Fig. 7C).
In spite of the local perturbations in the residuals, it is worth doing
calculations based on the weights in the ﬁts and on the amounts of
the components at the different locations/compositions of the pastilles.
These results are shown in Fig. 8.
As shown in Fig. 8 the sums are close to 1 (or exceed 1 if we take
the averages of the repeated measurements at the different shell lo-
cations), except for the cores, where they are considerably below
one. This difference results from the lower weights of sorbitol and
xylitol spectra in the core measurements. This can be explained if
we suppose that a new entity is formed from these compounds of dif-
ferent Raman spectra, that we could not consider in the ﬁts, and
there is obviously more time to form this entity in the core than in
the shell which cools faster. Indeed, the Raman spectrum of the xyli-
tol–sorbitol eutectic (not shown) exhibited very different peak ratios
in the 800–1200 cm−1 region as compared to its constituents. This
fact further supports the complex formation of sorbitol and xylitol
as suggested by the localized errors in the differences of the
measured and the component-reconstituted Raman spectra of the
pastilles (see the text above and Fig. 7C).
3.3.3. FT-IR analysis of the eutectic and the physical mixture
FT-IR measurements were carried out to investigate the interaction
between xylitol and sorbitol. Both a physical mixture and the eutectic
of the sugar alcohols were examined and their spectra were compared
to each other (Fig. 9).
Within the range of 900–600 cm−1, the spectrum of the physical
mixture contains vibrations of C structure's deformation. These bands
decrease remarkably in the spectrum of the eutectic, indicating that
the product is in the amorphous state. On the other hand, it also denotes
the presence of chemical bondings within the product (Jójárt-
Laczkovich and Szabó-Révész, 2011). In case of sugar alcohols, the
non-hydrogen bonded OH groups absorb strongly in the 3700–
3584 cm−1 range, where we could not observe a strong absorption. In-
termolecular hydrogen bondings occur as concentration increases, ac-
companied by an absorption shift to lower frequences (3550–
3200 cm−1, typically at 3300 cm−1), at the expense of the free OH
band, which could be observed. These data conﬁrm the presence of H-
bondings in the eutectic, which caused the anomalywhen ﬁtting the re-
siduals at the Raman evaluation.
3.3.4. Geometrical parameters and hardness
The mass of 20 pastilles of different compositions were measured
using an analytical scale and their diameter and height were measured
Fig. 7.Raman spectroscopy of paracetamol-containing pastilles. (A) Spectra of the individual components. (B) Raman spectra of the pastilles (EuPCT – eutecticmixture+PCT) at different
locations (shell and core) and in the presence of different PEGmolecules (2000 – PEG 2000, 6000 – PEG 6000). The spectra are vertically displaced for a better visibility. Overlaid spectra
represent repetitions on the same type of pastille surface at different locations. (C) The errors of the Raman spectra of the pastilles when ﬁtted with the linear combination of the
component spectra. Insert seen in part C: Raman spectrum of a similar paracetamol-containing pastille that contains no sorbitol. Note the smooth residual spectrum.
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using a screw micrometer. In average, mass of the pastilles was 279 ±
2 mg, the diameter was 11.2 ± 0.4 mm and the height was 3.5 ±
0.2 mm. Breaking hardness was measured on 5 pastilles. The average
breaking hardness of the pastilles made of the eutectic plus PCT combi-
nation was 29 ± 5 N, while that of the pastilles made of the
eutectic + PEG 2000 + PCT was 27 ± 6 N and average breaking hard-
ness value for the pastilles made of the eutectic + PEG 6000 + PCT
was 27 ± 4 N.
3.3.5. Drug content analysis
The drug contents of the pastilles of different compositionswere de-
termined spectrophotometrically. Three different batches of each com-
position were investigated. Average PCT contents of the pastilles were
found to be 39.9 ± 0.3 mg (eutectic), 40 ± 0.2 mg (eutectic + PEG
2000) and 40.1 ± 0.2 mg (eutectic + PEG 6000).
3.3.6. In vitro dissolution studies
After recrystallization of the components within the pastilles
(5 days), in vitro dissolution studies were carried out. In three parallel
measurements, PCT dissolutions of the pastilles of different composi-
tionswere compared at the oral cavity pH (pH 6.8±0.1) and in the gas-
tric juice (pH 1.2 ± 0.1) (Figs. 10 and 11).
In all three cases, PCT was found to be practically fully dissolved in
the medium of the oral cavity (pH 6.8 ± 0.1) within 20 min.
In the acidic medium (pH 1.2 ± 0.1) PCT also practically fully dis-
solved from PEG-containing pastilles within 20 min, while pastilles
Fig. 8.Weights of the components in the ﬁts of pastille spectra recorded at different locations/compositions calculated from normalised spectra. Note that the sum of theweights for each
ﬁt should equal to 1 as shown by the dashed line.
Fig. 9. (A) FT-IR spectra of the physical mixture and the eutectic, and (B) the enlarged spectra within the wavenumber range of 900–600 cm−1 after ﬁtting the curves on each other.
Fig. 10. Extents of dissolution of drop-meltedpastilles at the oral cavity pHof 6.8±0.1 and
at a temperature of 37 ± 0.5 °C (average value ± SD, n = 3).
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without PEG dissolved after 30 min only. These differences in the ex-
tents of dissolution can be explained by the differences in the surface
free energies of the pastilles. A lower surface free energy of the PEG-con-
taining pastilles resulted in a higher polarity and a faster dissolution
compared to the pastilles without PEG. Thus, it can be concluded that
using PEGs improves wettability and therefore the dissolution time of
the pastilles. When the pastille is swallowed, full liberation of PCT
lasts 5 min longer than in the mouth, which justiﬁes the formulation
of a pastille dosage form, compared Fig. 10 to Fig. 11.
4. Conclusions
The focus of our current research was to produce PCT-containing
pastilles using an in situ coating technology with additives (PEG 2000
and 6000). The eutectic composition of sorbitol and xylitol was ﬁrst de-
termined by constructing the binary phase diagram and the Tamman
triangle from the DSC data. Both methods conﬁrmed that sorbitol and
xylitol form a 50–50 wt.% eutectic mixture. Contact angle measure-
ments showed that wettability can be improved by using PEGs in the
formulations, keeping in mind that the viscosity-changing effect of
PEGs strongly depends on their molecular weight. Analytical studies of
the pastilles of different compositions revealed that solidiﬁcation oc-
curred in the pastilles and the shell consisted of xylitol, sorbitol and
PCT. Raman measurements showed a homogenous distribution of the
components within the pastilles. Our X-ray scattering, Raman and FT-
IR measurements made it evident that sorbitol and xylitol form a new
entity, which is characterized by a distinguished crystal structure and
speciﬁc intermolecular interactions. Our in vitro dissolution studies
showed that the extent of PCT dissolution was faster from the pastilles
containing PEGs compared to the pure eutectic (30 min). The pastille
containing PEG 2000 showed the fastest dissolution in the mouth, be-
cause of its lower surface free energy and higher polarity.
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The aim of this work was an investigation of the physical changes of the amorphous model material spray-dried
trehalose through the use of various analytical techniques and to identify a suitable, rapid method able to quan-
tify the changes. The crystallinity changes and recrystallization process of amorphous samples were investigated
by hot-humidity stage X-ray powder diffractometry (HH-XRPD)with fresh samples, conventional X-ray powder
diffractometry (XRPD) used stored samples and by differential scanning calorimetry (DSC). The data from the
three methods were compared and the various forms of trehalose were analysed. HH-XRPD demonstrated that
the recrystallization began at 40 and 60 °C up to 45% RH and at 70 °C up to 30% RH into dihydrate form. At
70 °C up to 60% RH the anhydrous form of trehalose appeared too. Conventional XRPD results showed, that in
the 28 days stored samples the dihydrate form was detected at 40 °C, 50% RH. Storage at 60 °C, 40% RH resulted
in the appearance of the anhydrous form and at 60 °C, 50% RH both polymorphic forms were detected. By carry-
ing out the DSC measurements at different temperatures the fraction of recrystallized trehalose dihydrate was
detected. The recrystallization investigated by HH-XRPD and DSC followed Avrami kinetics, the calculated rate
constants of isothermal crystallization (K) were same. Both HH-XRPD and conventional XRPD was suitable for
the detection of the physical changes of the amorphous model material. DSC measurements showed similar re-
sults as HH-XRPD. Primarily HH-XRPD could be suggested for prediction, because the method is fast and every
changes could be studied on one sample.
© 2016 Elsevier B.V. All rights reserved.
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1. Introduction
Trehalose is a natural sugar, but it is also synthesized and produced
on a large scale industrially. It is widely applied in the cosmetic, agricul-
tural, food and drug industries. In drug formulations, it is utilized as an
active pharmaceutical ingredient or as a technological auxiliary agent.
Trehalose could be also an active agent as chemical chaperone which
is used to treat Creutzfeldt-Jakob disease, cystic ﬁbrosis and amyloid
disorders that prevent protein aggregation (Aguib et al., 2009). In oral
medication, it displays antidepressant properties in the mouse model
of depression, possibly through reducing the p62/Beclin-1 ratio and in-
creasing autophagy in the frontal cortex (Kara et al., 2013).
The most important applications of trehalose as a pharmaceutical
excipient are to preserve enzymes, to stabilize vaccines at room temper-
ature for storage, and to protect mammalian cells from damage during
lyophilization. Trehalose concentrates the water near the protein, and
it can be transformed to its native structure after lyophilization and re-
gain its function (Timasheff, 2002). The protein-stabilizing ability of
trehalose is utilized in many areas of industry, e.g. as a moisturizer or
to stabilize liposomes (Tanaka et al., 1992). As an auxiliary component,
it is often applied as a carrier of dry powder inhalation (DPI) systems.
For this purpose, α-lactose monohydrate is normally used, but lactose
may reactwith the amino group, so proteins andpeptides cannot be for-
mulated with it. In this case, lactose must be substituted with trehalose,
rafﬁnose or sucrose. These non-reducing sugars have the common ad-
vantage of protecting proteins or peptides against different stress condi-
tions during spray-drying. They substitute the hydrogen-bonds in
water, and form viscous mixtures with proteins, resulting in products
with high glass temperatures of the product (Maas et al., 2011).
Trehalose is often produced as an excipient by spray-drying (Ógáin
et al., 2011; Islam and Gladki, 2008; Gradon and Sosnowski, 2014;
Pomázi et al., 2011; Maurya et al., 2005a; Maurya et al., 2005b; Moran
and Buckton, 2007a; Amaro et al., 2015), freeze-drying (Murugappan
et al., 2013; Nakamura et al., 2008; Crowe et al., 2003; Jovanovoc et al.,
2006; Claus et al., 2011) and spray-freeze-drying (Tonnis et al., 2014;
Yu et al., 2006) in pharmaceutical technology. Trehalose tends to under-
go amorphization, and the amorphous form is readily prepared by using
a solvent method such as spray- or freeze-drying. The recrystallization
kinetics can be followed which is important because of the appearance
of polymorph forms (Sussich and Cesáro, 2008). Trehalose has 4
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polymorphic forms (Table 1). This is especially important in the case of
DPI because of the preparation methods and the storage conditions of
the product. In this work one of the most efﬁcient amorphization tech-
nology, spray-drying was selected for preparing amorphous trehalose.
This method results in a monodisperse product with suitable particle
size and excellent ﬂowability.
Various analytical methods are available to investigate
amorphization (Jójárt-Laczkovich and Szabó-Révész, 2010;
Jójárt-Laczkovich and Szabó-Révész, 2011; Danciu et al., 2014; Jug and
Bećirević-Laćan, 2004), recrystallization, polymorphic conversions,
and the dehydration and rehydrationmechanisms of differentmaterials
(Szakonyi and Zelkó, 2012). Common techniques are differential scan-
ning calorimetry (DSC) and X-ray powder diffraction (XRPD) measure-
ments. Besides these possibilities, dynamic vapour sorption (Jones et al.,
2006), Karl Fischer moisture titration, isothermal thermogravimetric
analysis (Taylor and York, 1998) and simultaneous techniques (DSC-
XRPD and TG-DTA) have also been described in the case of trehalose
(Furuki et al., 2005; Mah et al., 2015). A modern investigation method
is hot-humidity stage X-ray powder diffraction (HH-XRPD), whereby
temperature and RH are variable. Through HH-XRPD analysis, complex
pharmaceutical solid-state reactions, including crystal structure trans-
formations, can be in situ characterized and followed. This method rap-
idly provides information about polymorph conversions and
recrystallization kinetics, and short-term stability testing can be carried
out during preformulation studies. Examples of the polymorphic trans-
formation of some active and auxiliary agents (naloxone, naltrexone
and aspartame) are to be found in the literature (Guguta et al., 2009;
Guguta et al., 2008).
The focus of this work was an investigation of the recrystallization
process of the amorphous model material spray-dried trehalose and to
ﬁnd a suitable method to predict the recrystallization of amorphous
sample during a preformulation study. In a comparison study three, dif-
ferent methods (HH-XRPD, XRPD, DSC) were used to analyse the crys-
tallinity changes.
2. Materials and methods
2.1. Materials
D-(+)-trehalose dihydrate h-form was purchased from Karl Roth
GmbH+ Co. KG. (Karlruhe, Germany). This was regarded as 100% crys-
tallinematerial. Thewater contentwas 9.5±0.5% and the sulphate con-
tent was b0.5%. Its speciﬁc rotation was 178 ± 2°.
Anhydrous D-(+)-trehalose β-form was produced by dehydration
of trehalose dihydrate at 85 °C during 4 h under vacuum (Nagase
et al., 2002) and checked the within 24 h both with DSC and XRPD.
2.2. Preparation of spray-dried trehalose
Trehalose dihydrate was spray-dried from 10% solutions in water
(5 g of trehalose and 45 g of water), using a Büchi 191 Mini Spray
Dryer (Büchi, Switzerland). The parameters used are given in Table 2
(Moran and Buckton, 2007b). The spray-dried products were stored in
a desiccator over cobalt(II) chloride-contaminated silicon dioxide
(25 ± 2 °C, 32 ± 5% RH) until use and were X-ray amorphous.
2.3. Preparation of physical mixtures
Physical mixtures of spray-dried (amorphous) and the two different
crystalline form of trehalose were prepared to achieve 0, 5, 10, 30, 50,
70, 90, 95 and 100% crystalline content by mass. The components
were weighed to a total amount of 0.50 g andweremixed homogenous
in a trituration mortar.
2.4. HH-XRPD
HH-XRPD analysis was performed on the spray-dried amorphous
sampleswithin 24 h by using a Bruker D8 Advance X-rayDiffractometer
(Bruker AXS GmbH, Karlsruhe, Germany) with Cu K λI radiation (λ=
1.5406 Å) installed with an MRI Basic hot-humidity stage and a
VÅNTEC-1 detector. The samples were scanned at 40 kV and 40 mA.
The angular range was from 3° to 40° 2θ, at a step time of 0.1 s and a
step size of 0.007°. An ANS-Sycoshot humidity control device was
coupled to the XRPD, which injected humidity into a controlled dry
gas ﬂow. The carrier gas was compressed air with a 0.5 l/min ﬂow.
The sample was taken in a Ni-coated sample holder. The RH was set at
10, 20, 30, 40, 45, 50, 60 and 70% at 40 °C, 60 °C and 70 °C controlled
temperatures, and the samples were kept in each condition for 1 h be-
fore measurement. All manipulations, Kα 2-stripping, background re-
moval and signal to noise smoothing of the area under the peaks of
diffractograms were performed with DIFFRACTPLUS EVA software.
2.5. XRPD
XRPD analysis was performedwith a Bruker D8Advance diffractom-
eter (Bruker AXS GmbH, Karlsruhe, Germany) with Cu K λI radiation
(λ= 1.5406 Å) and a VÅNTEC-1 detector. Both the physical mixtures
and the stored amorphous samples were scanned at 40 kV and 40 mA.
The angular range was 3° to 40° 2θ, at a step time of 0.1 s and a step
size of 0.007°. The sample was placed on a quartz holder, measured at
ambient temperature and RH. All manipulations, Kα 2-stripping, back-
ground removal and smoothing of the area under the peaks of
diffractograms were performed with DIFFRACTPLUS EVA software. The
determination of the polymorph form was based on the Cambridge
Crystallographic Data Centre (CCDC ID: AI631510) X-ray powder
diffractograms.
2.6. Storage conditions
One part of the spray-dried product was stored in a desiccator over
cobalt(II) chloride-contaminated silicon dioxide (25 ± 2 °C, 32 ± 5%
Table 1
Melting points of trehalose polymorphs (Sussich and Cesáro, 2008).
Polymorph Melting point (°C)
Trehalose-α (anhydrous) 120
Trehalose-β (anhydrous) 215
Trehalose-γ (anhydrous) 118–122
Trehalose-h (dihydrate) 100–110
Table 2
Operation parameters for the preparation of spray-dried trehalose.
Operating parameters Settings
Inlet temperature (°C) 130–140
Outlet temperature (°C) 75–92
Feed rate (ml/min) 2
Pressure (bar) 4,8
Atomizer ﬂow rate (normolitre/h) 600
Aspirator (%) 80
Table 3
Different storage conditions of amorphous samples.
Temperature (°C) Relative humidity (%) Storage time (day)
25 ± 2 32 ± 5 1
40 ± 2 30 ± 5 28
40 ± 5 28
50 ± 5 28
60 ± 2 30 ± 5 28
40 ± 5 28
50 ± 5 28
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RH) until HH-XRPD measurements. The reminder was divided into 6
parts and stored for 28 days at 40 °C and 60 °C, in 3-3 hygrostats,
where the RH was set to 30%, 40% and 50% RH. In each dessicator and
hygrostates, there was a digital humidity meter during the storage for
controlling the relative humidity. These samples were investigated
with XRPD (Table 3).
2.7. Calculation of the recrystallization kinetics
The recrystallization kinetics was modelled by using the Avrami
equation (Eq. (1)):
1−α ¼ exp −Ktnð Þ ð1Þ
where α is the fraction of recrystallized trehalose at time t, K is the rate
constant and n is the Avrami index, a parameter characteristic of the nu-
cleation and growth mechanism of crystals.
The fraction of recrystallized trehalose (α) was calculated from the
area under the characteristic peaks using the following equation
(Eq. (2)):
α ¼ Acrystalline
Acrystalline þ Aamorphous
100 ð2Þ
whereα is the crystalline fraction, A is the area of characteristic crystal-
line peaks and amorphous sign. Three characteristic peaks eachwere se-
lected from the diffractograms of trehalose dihydrate (at 8.531°, 12.552°
and 14.224° 2θ) and anhydrous trehalose (at 6.572°, 20.351° and
24.792° 2θ). The XRPD instrumentwas calibrated every daywith corun-
dum during the 28 days measurement to minimalize the day to day in-
tensity changes in XRPD emission.
The Avrami parameters were obtained from the experimental data
by using the double logarithmic form of Eq. (1):
ln − ln 1−αð Þ½  ¼ lnK þ n lnt ð3Þ
The activation energy of the recrystallizationwas calculated by using
the Arrhenius equation (Eq. (4)):
k ¼ k0 exp − EaRT
 
ð4Þ
In the model, k is the rate constant at temperature T, k0 is the fre-
quency factor, R is the gas constant and Ea is the activation energy. The
logarithmic form of Eq. (4) allows determination of the activation
Fig. 1. Relation between predicted and actual crystallinity of physical mixtures of crystalline trehalose dihydrate - amorphous form (A), anhydrous trehalose - amorphous form
(B) determined by conventional X-ray powder diffraction.
Table 4
The degree of crystallinity calculated from the HH-XRPD data (A: amorphous, h-form:
dihydrate, β-form: anhydrous).
Time [min, RH%] Form of trehalose Degree of crystallinity
(%)
40 °C 60 °C 70 °C 40 °C 60 °C 70 °C
0, 0 A A A 0 0 0
60, 10 A A A 0 0 0
120, 20 A A A 0 0 0
180, 30 A A h-form 0 0 11.7
240, 40 A A h-form 0 0 31.1
300, 45 h-form h-form h-form 14.8 27.2 65.2
360, 50 h-form h-form h-form 35.8 62.4 100
420, 60 h-form h-form β/h-form 70.2 78.8 100
480, 70 h-form h-form β/h-form 100 100 100 Fig. 2. The recrystallized trehalose polymorphs at 40, 60 and 70 °C controlled
temperatures.
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energy (Eq. (5)) (Mazzobre et al., 2001):
lnk ¼ lnk0− EaRT ð5Þ
2.8. DSC
DSCmeasurementswere carried outwith aMettler-Toledo 821e DSC
instrument (Mettler-Toledo GmbH, Switzerland). Samples loaded at
different RH (10, 20, 30, 40, 45, 50 and 70%) in the XRPD humidity
chamber for 1 h were crimped in aluminium pans with three holes
and were examined in the temperature interval 25–250 °C at a heating
rate of 10 °Cmin−1 under a constant argon ﬂow of 150mlmin−1. Every
measurement was normalized to sample size. The fraction of recrystal-
lized trehalose dihydrate was calculated from the integral of sharp en-
dotherm at 108 °C.
3. Results and discussion
3.1. Determination of calibration curves with XRPD
The peak intensities of the individual components are proportional
to the quantities of components in the mixture. Three characteristic
peaks eachwere selected from thediffractogramsof trehalose dihydrate
(at 8.531°, 12.552° and 14.224° 2θ) and anhydrous trehalose (at 6.572°,
20.351° and 24.792° 2θ). Multiple linear regression (MLR) was used to
determine the calibration curve. The dependent variable was the crys-
tallinity and the independent variables were the relative intensity
values at chosen 2θ values. After determination of the degree of crystal-
linity from w/w ratio of the physical mixtures, a calibration curve was
ﬁtted. Linear regression of the data produced an r2 = 0.995 and a
slope of 0.990 for trehalose dihydrate (Fig. 1A). For anhydrous trehalose,
r2 = 0.997 and the slope was 0.997 (Fig. 1B).
Because of the well-correlating r2 values the degree of crystallinity
can be quantiﬁed.
3.2. Calculation of crystallization kinetics
3.2.1. Hot-humidity stage XRPD analysis
For the development and qualiﬁcation of solid compositions it is im-
portant to investigate and determine changes of the crystalline phases
or the effect of crystallization inhibitor, when materials are exposed to
changing humidity and temperature. Increasing the humidity in small
intervals (10%) at the exact temperature, good estimation could be
gained during fewhours at the exact temperature about the samples be-
haviour,which could be reﬂected on the results of conventional stability
test. There is no need for additional hygrostats and extra samples, the
measurement takes place directly in the chamber conducted to the in-
strument. These investigations are not only important to establish pro-
cedures for storage, production and shipment, but also emulate the
indigestion of the respective drug and its ﬁrst interactions with the
Fig. 3. Crystallization kinetics by ﬁtting the Avrami equation to the HH-XRPD data.
Fig. 4. Determination of the Avrami parameters n and K from HH-XRPD data.
Fig. 5. Top-viewpictures of XRPD investigations of samples stored for 28 days at 40 °C, 50%
RH (A), 60 °C, 40% RH (B) and 60 °C, 50% RH (C).
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patient. In this contextHH-XRPDwasused to predict the tendency to re-
crystallization, which is presented in Table 4.
The samples measured at 40 and 60 °C were amorphous up to 45%
RH,when recrystallization began in the trehalose dihydrate polymorph.
The samples measured at 70 °C were amorphous up to 30% RH, than
they recrystallized to dihydrate form and up to 60% RH the anhydrous
form appeared too. The determination of the polymorph forms was
based on the Cambridge Crystallographic Data Centre (CCDC ID:
AI631510) X-ray powder diffractograms (Fig. 2).
The diffractogramsmeasured at 40, 60 and 70 °C showed an increas-
ing tendency to recrystallization. The relative intensities and integrals of
the peaks increased with the temperature, and the temperature there-
fore inﬂuences the tendency of trehalose to recrystallize.
To investigate the temperature dependence of recrystallization, the
recrystallized fractions were plotted against time for each temperature.
As the calibration showed, before XRPD the method could be used for
quantitative measurements. The curves obtained by ﬁtting the Avrami
Eq. (1) were in good agreement (r2 N 0.992) with the experimental
points (Fig. 3).
The sigmoidal curves showed that increased temperature acceler-
ates the recrystallization and reduces the crystallization half-time. To
acquire information about the velocity of the process and the dimen-
sions of crystal growth, the parameters K and n were determined by
using the linearized Avrami equation (Eq. (3)) (Fig. 4) and the activa-
tion energy was calculated via the logarithmic form of the Arrhenius
model (Eq. (5)) (Table 7).
3.2.2. Analysis of samples stored in hygrostats (XRPD)
To the comparison study amorphous samples were stored for
28 days at 40 °C and 60 °C in 3 hygrostats each, where the RH had
been set to 30%, 40% and 50%. The fractions of recrystallized trehalose
were measured at different times during the 28 days of storage. The
conventional XRPD analysis showed, that the samples stored at 40 °C,
30% and 40% RH, and at 60 °C, 30% RH remained amorphous. The sam-
ples stored at 40 °C, 50% RH recrystallized in the dihydrate form. The
storage conditions at 60 °C, 40% RH, resulted in recrystallization of the
anhydrous form, and in the sample stored at 60 °C, 50% RH, both poly-
morphs appeared, the h-form (dihydrate) and the β-form (anhydrous)
(Fig. 5).
Fig. 5B shows that the stripe at 8.531° 2θ disappears after storage for
14 days, and there is a polymorph conversion of trehalose dihydrate
into the anhydrous form, conﬁrmed by the characteristic thick stripe
at 6.572° 2θ. Fig. 5A and C do not indicate any polymorph conversion.
The diffractograms measured after 28 days storage are shown in Fig. 6.
The degree of crystallinity of the recrystallized polymorphs was cal-
culated by evaluating the diffractograms in Fig. 6 according to the MLR
model. The results showed that amorphous fractions remained in the
samples, but decreased at higher temperature and RH (Table 5).
By means of the 28-days stability tests, the different recrystallized
polymorph forms can be detected and quantiﬁed. The results showed
that, at 40 °C and 50% RH the dihydrate was detected, but the bulk of
the investigated sample remained amorphous. Storage at 60 °C and
40% RH resulted in the appearance of the anhydrous form and only a
minor proportion of the sample remained amorphous. At 60 °C and
50% RH, both polymorphic forms were detected and almost the whole
sample recrystallized. This conventional method is often used as a
long-term stability test in the development of a drug delivery system.
Fig. 6. Diffractograms of samples stored for 28 days under different conditions, compared
with trehalose forms in CCDC.
Table 5
The degree of crystallinity calculated from the XRPD data after 28 days.
Condition [°C, RH%] Form of trehalose Quantity (%)
Amorphous Dihydrate (h-form) Anhydrous (β-form) Amorphous Dihydrate (h-form) Anhydrous (β-form)
40, 30 + − − 100 0 0
40, 40 + − − 100 0 0
40, 50 + + − 63.1 36. 9 0
60, 30 + − − 100 0 0
60, 40 + − + 25.5 0 74.5
60, 50 + + + 0.4 58.2 41.5
Table 6
ΔH ofmelting and the crystalline fraction (α) at different temperatureswith increasing the
RH.
ΔH (J g−1) α (%)
RH (%) 40 °C 60 °C 70 °C 40 °C 60 °C 70 °C
30 – – 17.1 0 0 11
40 – – 27.3 0 0 17.6
45 44.5 33.0 128.1 28.7 21.3 82.7
50 63.8 66.0 137.6 41.2 42.6 88.8
60 130.4 123.5 141.4 84.2 79.7 91.3
70 153.5 153.0 153.8 99.1 98.8 99.3
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3.2.3. DSC investigation
The amount of recrystallized trehalose dihydrate was calculated
from the integral of the endothermic peaks at 108 °C, which is themelt-
ing point of trehalose dehydrate β-form. Table 6 shows the enthalpy
changes (ΔH) of melting and the calculated crystalline fraction (α) at
different temperature increasing the RH.
The amount of crystalline fractions showed, that the recrystallization
of the amorphous sample is more signiﬁcant with increasing RH and at
70% RH total recrystallization of the samples occurred at all 3 tempera-
tures. Comparison of these results with those in Table 4 shows that DSC
andHH-XRPDmeasurements correlate well.With thismethod, only the
fraction of recrystallized trehalose dihydrate can be determined. Since
the anhydrous form has high melting point, the dihydrate form is con-
versed into the anhydrous form resulting in false measurement data.
However, the method can be used for fast stability testing during the
preformulation.
The crystalline fractions calculated from theDSC data (Table 6)were
plotted against time for each temperature with r2 N 0.983 (Fig. 7).
The sigmoidal curves showed that increased temperature acceler-
ates the recrystallization, and reduces the crystallization half-time. To
acquire information about the velocity of the process and the dimen-
sions of crystal growth, the Avrami parameters should be determined.
The parameters K and n were determined by using the linearized
Avrami equation (Eq. (3)). A plot of ln [-ln (1-α)] against ln (t) yields
a straight line with slope n and intercept ln K (Fig. 8). The activation en-
ergy was calculated via the logarithmic form of the Arrhenius model
(Eq. (5)). Table 6 shows the parameters of the recrystallization process.
The values of rate constant K show that increasing temperature ac-
celerates the recrystallization process. There are differences between
the measurement results of the two methods, but the results correlate
well. Comparison of the HH-XRPD data with the DSC measurements
demonstrates that increasing temperature accelerates the recrystalliza-
tion and reduces the crystallization half-time. The parameters K and n
were determined by using the linearized Avrami equation (Eq. (3))
(Fig. 8).
4. Conclusions
In the comparison study the three analytical methods (HH-XRPD,
XRPD, DSC)were used to investigate the recrystallization of amorphous
trehalose. The focus of this work was to suggest such method, which is
sensitive and rapid to predict the recrystallization process in the
preformulation study.
HH-XRPD was used to investigate the effects of temperature and
rapid RH changes. Different RH conditions resulted in different crystal-
line forms of trehalose, whichmeans that recrystallization can start dur-
ing the process of the investigation. In this way, the control of
crystallinity is necessary. The measurement demonstrated that the re-
crystallization began at 40 and 60 °C up to 45% RH and at 70 °C up to
30% RH into dihydrate form. At 70 °C up to 60% RH, the anhydrous
form of trehalose appeared too. It could be concluded that the temper-
ature and RH dependence of recrystallization are determining factors.
This can be expressed in a numerical relationship by the Avrami and Ar-
rhenius equations. HH-XRPD is a good choice for gaining a good estima-
tion over a few hours about the samples behaviour, which could be
reﬂected on the results of a conventional stability test.
The conventional storage at different temperatures and RH gave in-
formation about the recrystallized polymorphs. Over the course of
28 days, both RH and temperature changes can cause the recrystalliza-
tion of amorphous trehalose. The dihydrate form was detected at
40 °C, 50% RH. Storage at 60 °C, 40% RH resulted in the appearance of
the anhydrous form and at 60 °C, 50% RH both polymorphic forms
were detected. In this light, the suitable choice of the storage conditions
can protect the amorphous trehalose samples from crystallization.
By carrying out the DSC measurements at different temperatures,
the fraction of recrystallized trehalose dihydrate can be determined.
The degree of crystallinity of trehalose dihydrate determined by DSC
correlated well with the HH-XRPD measurements.
It could be concluded that HH-XRPD is faster than other convention-
al techniques and a good prediction for the recrystallization of amor-
phous compounds during preformulation, moreover the physical
changes could be studied on one sample.
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